Quarterly Information - ITR

Diagnósticos da América S.A.

June 30, 2014

Contents

Company Data

Capital Stock Composition 1
Cash Earnings........ 2

INDIVIDUAL QUARTERLY FINANCIAL INFORMATION

Statement of Financial Position – Assets........ 3
Statement of Financial Position – Liabilities 4
Statement of Income 5
Statement of Comprehensive Income........ 6
Statement of Cash Flows........ 7
Statement of Changes in Equity
1/1/2014 to 6/30/2014 8
1/1/2013 to 6/30/2013 9
Statement of Value Added 10

CONSOLIDATED QUARTERLY FINANCIAL INFORMATION

Statement of Financial Position – Assets........ 11
Statement of Financial Position – Liabilities 12
Statement of Income 13
Statement of Comprehensive Income........ 14
Statement of Cash Flows........ 15
Statement of Changes in Equity
1/1/2014 to 6/30/2014 16
1/1/2013 to 6/30/2013 17
Statement of Value Added 18
Comments on the Company's Performance 19
Notes to Quarterly Financial Information........ 27
Other Information Considered Relevant by the Company 92

Reports and Representations
Independent Auditor's Review Report on Quarterly Financial Information........ 93
Opinions and Statements/Statement of Officers on the Quarterly Financial Information........ 95
Opinions and Declarations/Statement of Officers on the Independent Auditors Review Report........ 96

Company data / Capital Composition

Number of shares (Units)	Current quarter 6/30/2014
Paid-in capital	
Common shares	311,803,015
Preferred shares	-
Total	311,803,015
Treasury shares	
Common shares	1,152,459
Preferred shares	-
Total	1,152,459

Company Data / Cash Earnings

Event	Approval	Earnings	Initial Payment	Share	Class of Share	Earnings per share (Reais / Share)
Annual General Meeting	4/28/2014	Dividends	6/16/2014	Common		0.10100

Individual Quarterly Financial Information / Statement of Financial Position – Assets

(R$ in thousands)

Code	Description	Current Quarter 6/30/2014	Previous Year 12/31/2013
1	Total assets	4,316,817	4,480,344
1.01	Current assets	828,984	1,055,844
1.01.01	Cash and cash equivalents	238,306	486,571
1.01.03	Accounts receivable	410,118	389,860
1.01.03.01	Trade accounts receivable	410,118	389,860
1.01.04	Inventories	43,044	40,406
1.01.06	Taxes recoverable	111,172	107,299
1.01.06.01	Current taxes recoverable	111,172	107,299
1.01.07	Prepaid expenses	3,449	883
1.01.08	Other current assets	22,895	30,825
1.01.08.03	Other	22,895	30,825
1.01.08.03.01	Derivative financial instruments	-	85
1.01.08.03.20	Other receivables	22,895	30,740
1.02	Non-current assets	3,487,833	3,424,500
1.02.01	Long-term receivables	138,007	143,012
1.02.01.01	Marketable securities at fair value	24,262	26,184
1.02.01.01.01	Marketable securities	24,262	26,184
1.02.01.03	Accounts receivable	714	295
1.02.01.03.01	Trade accounts receivable	714	295
1.02.01.07	Prepaid expenses	489	788
1.02.01.08	Receivables from related parties	75,882	25,000
1.02.01.08.02	Receivables from subsidiaries	75,882	25,000
1.02.01.09	Other non-current assets	36,660	90,745
1.02.01.09.03	Derivative financial instruments	-	22
1.02.01.09.04	Judicial deposits	36,632	90,695
1.02.01.09.05	Other non-current assets	28	28
1.02.02	Investments	540,384	453,127
1.02.02.01	Equity interest	539,741	452,503
1.02.02.01.02	Investments in subsidiaries	539,741	452,503
1.02.02.02	Investment properties	643	624
1.02.02.02.20	Others	643	624
1.02.03	Property and equipment	507,905	543,082
1.02.04	Intangible assets	2,301,537	2,285,279
1.02.04.01	Intangible assets	2,301,537	2,285,279

Individual Quarterly Financial Information / Statement of Financial Position – Liabilities

(R$ in thousands)

Code	Description	Current Quarter 6/30/2014	Previous Year 12/31/2013
2	Total liabilities	4,316,817	4,480,344
2.01	Current liabilities	560,419	565,634
2.01.01	Social security and labor liabilities	104,531	81,270
2.01.02	Trade accounts payable	55,691	45,804
2.01.03	Tax liabilities	11,055	10,476
2.01.04	Loans and financing	320,740	326,540
2.01.04.01	Loans and financing	3,381	6,628
2.01.04.02	Debentures	317,359	319,912
2.01.05	Other liabilities	68,402	101,544
2.01.05.02	Other	68,402	101,544
2.01.05.02.01	Dividends and interest on equity payable	8	31,188
2.01.05.02.04	Taxes in installments	867	1,108
2.01.05.02.05	Accounts payable for acquisition of subsidiaries	1,735	1,689
2.01.05.02.07	Financial instruments	310	-
2.01.05.02.08	Other payables	65,482	67,559
2.02	Non-current liabilities	987,308	1,206,496
2.02.01	Loans and financing	808,240	1,038,617
2.02.01.01	Loans and financing	3,718	1,803
2.02.01.02	Debentures	804,522	1,036,814
2.02.02	Other liabilities	42,945	48,174
2.02.02.02	Other	42,945	48,174
2.02.02.02.03	Taxes in installments	9,412	9,430
2.02.02.02.04	Accounts payable for acquisition of subsidiaries	30,818	35,061
2.02.02.02.05	Financial instruments	26	-
2.02.02.02.06	Other payables	2,689	3,683
2.02.03	Deferred taxes	88,978	82,211
2.02.03.01	Deferred income and social contribution taxes	88,978	82,211
2.02.04	Provisions	47,145	37,494
2.02.04.01	Provisions for tax, civil and labor risks	47,145	37,494
2.03	Equity	2,769,090	2,708,214
2.03.01	Paid-in capital	2,234,135	2,234,135
2.03.02	Capital reserves	50,464	49,727
2.03.02.02	Special reserve for goodwill on merger	65,366	65,427
2.03.02.04	Granted options	2,003	2,917
2.03.02.05	Treasury shares	(16,905)	(18,617)
2.03.04	Revenue reserves	483,862	423,409
2.03.04.01	Legal reserve	30,128	30,128
2.03.04.05	Retained profit reserve	453,734	393,090
2.03.04.08	Additional proposed dividend	0	191
2.03.06	Other comprehensive income	629	943

Individual Quarterly Financial Information / Statement of Income

(R$ in thousands)

Code	Description	Current quarter 4/1/2014 to 6/30/2014	Accumulated current period 1/1/2014 to 6/30/2014	Current quarter 4/1/2013 to 6/30/2013	Accumulated previous period 1/1/2013 to 6/30/2013
3.01	Revenue from products sold and/or services rendered	488,068	961,631	457,493	869,695
3.02	Cost of products sold and/or services rendered	(345,491)	(675,905)	(317,897)	(603,970)
3.03	Gross Profit	142,577	285,726	139,596	265,725
3.04	Operating income/expenses	(78,873)	(166,824)	(82,148)	(160,836)
3.04.02	General and administrative expenses	(109,166)	(224,167)	(94,156)	(189,227)
3.04.04	Other operating income	20	406	(131)	(70)
3.04.06	Equity pickup	30,273	56,937	12,139	28,461
3.05	Income before financial income/expenses and taxes	63,704	118,902	57,448	104,889
3.06	Financial income/expenses	(26,789)	(51,805)	(9,880)	(29,635)
3.06.01	Financial income	13,653	29,028	24,020	29,196
3.06.02	Financial expenses	(40,442)	(80,833)	(33,900)	(58,831)
3.07	Income before income and social contribution taxes	36,915	67,097	47,568	75,254
3.08	Income and social contribution taxes	(5,180)	(6,767)	(12,409)	(16,573)
3.08.02	Deferred	(5,180)	(6,767)	(12,409)	(16,573)
3.09	Net income from continuing operations	31,735	60,330	35,159	58,681
3.11	Net income for the period	31,735	60,330	35,159	58,681
3.99	Earnings per share (reais/share)				
3.99.01	Basic earnings per share				
3.99.01.01	Common shares	0.10212	0.19414	0.11318	0.18890
3.99.02	Diluted earnings per share				
3.99.02.01	Common shares	0.10205	0.19401	0.11306	0.18870

Individual Quarterly Financial Information / Statement of Comprehensive Income

(R$ in thousands)

Code	Description	Current quarter 4/1/2014 to 6/30/2014	Accumulated current year 1/1/2014 to 6/30/2014	Previous quarter 4/1/2013 to 6/30/2013	Accumulated previous year 1/1/2013 to 6/30/2013
4.01	Net income for the period	31,735	60,330	35,159	58,681
4.03	Comprehensive income for the period	31,735	60,330	35,159	58,681

Individual Quarterly Financial Information / Statement of Cash Flows

(R$ in thousands)

Code	Description	Accumulated current period 1/1/2014 to 6/30/2014	Accumulated previous period 1/1/2013 to 6/30/2013
6.01	Net cash from operating activities	173,129	123,556
6.01.01	Cash from operations	165,415	142,610
6.01.01.01	Net income for the period	60,330	58,681
6.01.01.02	Depreciation and amortization	71,692	66,016
6.01.01.03	Restatement of contingencies	13,652	5,423
6.01.01.04	Deferred taxes	6,767	16,573
6.01.01.05	Restatement of interest and exchange variation on loans	70,535	39,910
6.01.01.06	Gain on sale of property and equipment	483	2,043
6.01.01.07	Stock-option plan	737	399
6.01.01.08	Equity pickup	(56,937)	(28,461)
6.01.01.09	Gain on interest in subsidiaries	196	186
6.01.01.10	Provision for disallowance and default	(2,040)	(18,160)
6.01.02	Changes in assets and liabilities	7,714	(19,054)
6.01.02.01	Increase in trade accounts receivable and other receivables	(18,637)	(27,137)
6.01.02.02	(Increase) Decrease in inventories	(2,638)	2,340
6.01.02.03	Decrease in other current assets	1,406	3,645
6.01.02.04	Decrease (increase) in other non-current assets	5,383	(1,009)
6.01.02.05	Increase in trade accounts payable	9,887	6,148
6.01.02.06	Increase (Decrease) in accounts payable and provisions	12,313	(3,041)
6.02	Net cash used in investing activities	(83,753)	(44,061)
6.02.01	Additions to property and equipment	(45,258)	(47,922)
6.02.02	Additions to intangible assets	(8,030)	(16,100)
6.02.06	Investments in subsidiaries	(43,010)	-
6.02.08	Interest on equity received	12,513	19,961
6.02.09	Proceeds from sale of property and equipment	32	0
6.03	Net cash (used in) from financing activities	(337,641)	69,443
6.03.01	Loans received	3,405	0
6.03.02	Payment of loans	(236,926)	(9,864)
6.03.07	Dividends and interest on equity reserve paid	(31,371)	(20,500)
6.03.08	Interest paid	(72,749)	(39,079)
6.05	(Decrease) increase in cash and cash equivalents	(248,265)	10,052
6.05.01	At beginning of period	486,571	152,546
6.05.02	At end of period	238,306	162,598

Individual Quarterly Financial Information / Statement of Changes in Equity – 1/1/2014 to 6/30/2014

(R$ in thousands)

Code	Description	Paid-in Capital	Capital Reserve, Granted options and treasury shares	Income reserve	Retained earnings	Other comprehensive income	Equity
5.01	Opening balances	2,234,135	49,727	423,409	-	943	2,708,214
5.03	Adjusted opening balances	2,234,135	49,727	423,409	-	943	2,708,214
5.04	Transactions with shareholders	-	737	-	-	-	737
5.04.03	Granted options	-	737	-	-	-	737
5.05	Total comprehensive income	-	-	-	60,330	-	60,330
5.05.01	Net income of the period	-	-	-	60,330	-	60,330
5.06	Internal changes in equity	-	-	123	-	(314)	(191)
5.06.04	Depreciation of deemed cost	-	-	314	-	(314)	-
5.06.05	Additional dividends paid	-	-	(191)	-	-	(191)
5.07	Closing balances	2,234,135	50,464	423,532	60,330	629	2,769,090

Individual Quarterly Financial Information / Statement of Changes in Equity – 1/1/2013 to 6/30/2013

(R$ in thousands)

Code	Description	Paid-in Capital	Capital Reserve, Granted options and treasury shares	Income reserve	Retained earnings	Other comprehensive income	Equity
5.01	Opening balances	2,234,135	48,171	322,933	-	1,571	2,606,810
5.03	Adjusted opening balances	2,234,135	48,171	322,933	-	1,571	2,606,810
5.04	Transactions with shareholders	-	398	-	-	-	398
5.04.03	Granted options	-	398	-	-	-	398
5.05	Total comprehensive income	-	-	-	58,681	-	58,681
5.05.01	Net income for the period	-	-	-	58,681	-	58,681
5.06	Internal changes in equity	-	-	45	-	(314)	(269)
5.06.04	Depreciation of deemed cost	-	-	314	-	(314)	-
5.06.05	Additional dividends paid	-	-	(269)	-	-	(269)
5.07	Closing balances	2,234,135	48,569	322,978	58,681	1,257	2,665,620

Individual Quarterly Financial Information / Statement of Value Added

(R$ in thousands)

Code	Description	Accumulated current period 1/1/2014 to 6/30/2014	Accumulated previous period 1/1/2013 to 6/30/2013
7.01	Revenue	1,055,251	958,991
7.01.01	Sales of goods, products and services	1,054,912	959,091
7.01.02	Other revenue	406	(70)
7.01.04	(Reversal of) allowance for doubtful accounts	(67)	(30)
7.02	Inputs acquired from third parties	(513,502)	(450,904)
7.02.01	Cost of products, goods and services sold	(366,348)	(332,217)
7.02.02	Materials, energy, third-party services and other	(147,154)	(117,877)
7.03	Gross value added	541,749	508,897
7.04	Retentions	(71,692)	(66,016)
7.04.01	Depreciation, amortization and depletion	(71,692)	(66,016)
7.05	Net value added produced	470,057	442,881
7.06	Transferred value added received	85,965	57,657
7.06.01	Equity pickup	56,937	28,461
7.06.02	Financial income	29,028	29,196
7.07	Total value added to be distributed	556,022	500,538
7.08	Distribution of value added	556,022	500,538
7.08.01	Personnel	243,895	218,016
7.08.02	Taxes, fees and contributions	114,267	114,758
7.08.03	Debt remuneration	137,530	109,083
7.08.04	Equity remuneration	60,330	58,681
7.08.04.03	Retained profits	60,330	58,681

Consolidated Quarterly Financial Information / Statement of Financial Position – Assets

(R$ in thousands)

Code	Description	Current Quarter 6/30/2014	Previous Year 12/31/2013
1	Total assets	4,591,562	4,691,811
1.01	Current assets	1,417,707	1,438,626
1.01.01	Cash and cash equivalents	441,821	535,881
1.01.02	Marketable securities	55,822	72,980
1.01.02.01	Marketable securities at fair value	55,822	72,980
1.01.02.01.01	Securities for trading	55,822	72,980
1.01.03	Accounts receivable	639,582	566,262
1.01.03.01	Trade accounts receivable	639,582	566,262
1.01.04	Inventories	67,953	59,383
1.01.06	Taxes recoverable	178,274	169,696
1.01.06.01	Current taxes recoverable	178,274	169,696
1.01.07	Prepaid expenses	4,161	897
1.01.08	Other current assets	30,094	33,527
1.01.08.03	Other	30,094	33,527
1.01.08.03.01	Derivative financial instruments	-	85
1.01.08.03.20	Other receivables	30,094	33,442
1.02	Non-current assets	3,173,855	3,253,185
1.02.01	Long-term receivables	142,426	200,517
1.02.01.01	Marketable securities at fair value	36,384	37,793
1.02.01.01.01	Marketable Securities	36,384	37,793
1.02.01.03	Accounts receivable	4,906	5,940
1.02.01.03.01	Trade accounts receivable	4,906	5,940
1.02.01.06	Deferred taxes	58,812	58,002
1.02.01.06.01	Deferred income and social contribution taxes	58,812	58,002
1.02.01.07	Prepaid expenses	489	789
1.02.01.09	Other non-current assets	41,835	97,993
1.02.01.09.03	Derivative financial instruments	-	22
1.02.01.09.04	Judicial deposits	41,529	95,540
1.02.01.09.05	Other non-current assets	306	2,431
1.02.02	Investments	855	786
1.02.02.02	Investment Properties	855	786
1.02.02.02.01	Other	855	786
1.02.03	Property and equipment	682,296	720,180
1.02.04	Intangible assets	2,348,278	2,331,702
1.02.04.01	Intangible assets	2,348,278	2,331,702

Consolidated Quarterly Financial Information / Statement of Financial Position – Liabilities and Equity

(R$ in thousands)

Code	Description	Current Quarter 6/30/2014	Previous Year 12/31/2013
2	Total liabilities	4,591,562	4,691,811
2.01	Current liabilities	752,598	730,778
2.01.01	Social security and labor liabilities	132,656	103,659
2.01.02	Trade accounts payable	81,180	65,479
2.01.03	Tax liabilities	26,424	22,386
2.01.04	Loans and financing	427,040	420,854
2.01.04.01	Loans and financing	109,681	100,942
2.01.04.02	Debentures	317,359	319,912
2.01.05	Other liabilities	85,298	118,400
2.01.05.02	Other	85,298	118,400
2.01.05.02.01	Dividends and Interest equity payable	78	31,255
2.01.05.02.04	Taxes in installments	2,636	4,293
2.01.05.02.05	Accounts payable for acquisition of subsidiaries	1,735	1,689
2.01.05.02.07	Financial instruments	310	-
2.01.05.02.20	Other accounts payable	80,539	81,163
2.02	Non-current liabilities	1,069,079	1,252,223
2.02.01	Loans and financing	861,735	1,054,321
2.02.01.01	Loans and financing	57,213	17,507
2.02.01.02	Debentures	804,522	1,036,814
2.02.02	Other liabilities	67,481	75,246
2.02.02.02	Other	67,481	75,246
2.02.02.02.03	Taxes in installments	21,826	24,892
2.02.02.02.04	Accounts payable for acquisition of subsidiaries	42,940	46,670
2.02.02.02.05	Financial instruments	26	-
2.02.02.02.20	Other accounts payable	2,689	3,684
2.02.03	Deferred taxes	89,765	82,211
2.02.03.01	Deferred income and social contribution taxes	89,765	82,211
2.02.04	Provisions	50,098	40,445
2.02.04.01	Provisions for tax, civil and labor risks	50,098	40,445
2.03	Consolidated equity	2,769,885	2,708,810
2.03.01	Paid-in capital	2,234,135	2,234,135
2.03.02	Capital reserves	50,464	49,727
2.03.02.02	Special reserve for goodwill on merger	65,366	65,427
2.03.02.04	Granted options	2,003	2,917
2.03.02.05	Treasury Shares	(16,905)	(18,617)
2.03.04	Income reserves	483,862	423,409
2.03.04.01	Legal reserve	30,128	30,128
2.03.04.05	Retained profit reserve	453,734	393,090
2.03.04.08	Additional proposed dividend	0	191
2.03.06	Other comprehensive income	629	943
2.03.09	Non-controlling interest	795	596

Consolidated Quarterly Financial Information / Statement of Income

(R$ in thousands)

Code	Description	Current quarter 4/1/2014 to 6/30/2014	Accumulated current period 1/1/2014 to 6/30/2014	Current quarter 4/1/2013 to 6/30/2013	Accumulated previous period 1/1/2013 to 6/30/2013
3.01	Revenue from products sold and/or services rendered	687,401	1,349,546	631,333	1,212,920
3.02	Cost of products sold and/or services rendered	(471,716)	(923,974)	(434,153)	(836,763)
3.03	Gross profit	215,685	425,572	197,180	(376,157)
3.04	Operating income/expenses	(140,281)	(283,893)	(124,110)	(245,813)
3.04.02	General and administrative expenses	(140,591)	(284,973)	(125,705)	(247,804)
3.04.04	Other operating income	310	1,080	1,595	1,991
3.05	Profit before financial income/expenses and taxes	75,404	141,679	73,070	130,344
3.06	Financial income/expenses	(28,412)	(53,054)	(18,100)	(39,094)
3.06.01	Financial income	19,664	39,255	26,414	34,467
3.06.02	Financial expenses	(48,076)	(92,309)	(44,514)	(73,561)
3.07	Income before income and social contribution taxes	46,992	88,625	54,970	91,250
3.08	Income and social contribution taxes	(15,141)	(28,092)	(19,798)	(32,518)
3.08.01	Current	(8,664)	(21,348)	(11,118)	(20,034)
3.08.02	Deferred	(6,477)	(6,744)	(8,680)	(12,484)
3.09	Net income from continuing operations	31,851	60,533	35,172	58,732
3.11	Consolidated net income for the period	31,851	60,533	35,172	58,732
3.11.01	Attributed to controlling shareholders	31,735	60,330	35,159	58,681
3.11.02	Attributed to non-controlling shareholders	116	203	13	51
3.99	Earnings per share (reais/share)				
3.99.01	Basic earnings per share				
3.99.01.01	Common shares	0.10250	0.19480	0.11322	0.18907
3.99.02	Diluted earnings per share				
3.99.02.01	Common shares	0.10243	0.19466	0.11310	0.18886

Consolidated Quarterly Financial Information / Statement of Comprehensive Income

(R$ in thousands)

Code	Description	Current quarter 4/1/2014 to 6/30/2014	Accumulated current period 1/1/2014 to 6/30/2014	Current quarter 4/1/2013 to 6/30/2013	Accumulated previous period 1/1/2013 to 6/30/2013
4.01	Consolidated net income for the period	31,851	60,533	35,172	58,732
4.03	Consolidated other comprehensive income for the period	31,851	60,533	35,172	58,732
4.03.01	Attributed to controlling shareholders	31,735	60,330	35,159	58,681
4.03.02	Attributed to non-controlling shareholders	116	203	13	51

Consolidated Quarterly Financial Information / Statement of Cash Flows

(R$ in thousands)

Code	Description	Accumulated current period 1/1/2014 to 6/30/2014	Accumulated previous period 1/1/2013 to 6/30/2013
6.01	Net cash from operating activities	240,077	138,147
6.01.01	Cash from operations	237,624	194,376
6.01.01.01	Net income for the period	60,533	58,732
6.01.01.02	Depreciation and amortization	85,933	79,559
6.01.01.03	Restatement of contingencies	13,654	5,423
6.01.01.04	Deferred taxes	6,744	12,484
6.01.01.05	Restatement of interest and exchange variation on loans	68,862	50,438
6.01.01.06	Gain on sale of property and equipment	71	2,151
6.01.01.08	Stock-option plan	737	399
6.01.01.09	Restatement of interest and exchange variation on marketable securities	406	(597)
6.01.01.10	Provision for disallowance and default	684	(14,213)
6.01.02	Changes in assets and liabilities	11,590	(40,935)
6.01.02.01	Increase in accounts receivable and other receivables	(72,970)	(58,678)
6.01.02.02	(Increase) Decrease in inventories	(8,570)	3,854
6.01.02.03	Increase in other current assets	(8,500)	(14,043)
6.01.02.04	Decrease (Increase) in other non-current assets	57,873	(650)
6.01.02.05	Increase in trade accounts payable	15,701	4,047
6.01.02.06	Increase in accounts payable and provisions	28,146	24,535
6.01.03	Other	(9,137)	(15,294)
6.01.03.02	Income and social contribution taxes paid	(9,137)	(15,294)
6.02	Net cash used in investing activities	(47,944)	(70,332)
6.02.01	Additions to property and equipment	(56,524)	(54,072)
6.02.02	Additions to intangible assets	(8,380)	(16,260)
6.02.09	Proceeds from sale of property and equipment	208	-
6.02.12	Redemption of marketable securities for trading	16,752	-
6.03	Net cash used in financing activities	(286,193)	(89,608)
6.03.01	Loans received	63,405	202
6.03.02	Payment of loans	(243,360)	(25,451)
6.03.05	Payment of interest on loans	(31,372)	(20,500)
6.03.06	Dividends and interest on equity reserve paid	(74,866)	(43,859)
6.05	Decrease in cash and cash equivalents	(94,060)	(21,793)
6.05.01	At beginning of period	535,881	228,519
6.05.02	At end of period	441,821	206,726

Consolidated Quarterly Financial Information / Statement of Changes in Equity– 1/1/2014 to 6/30/2014

(R$ in thousands)

Code	Description	Paid-in Capital	Capital Reserve – Granted options and treasury shares	Income reserve	Retained earnings	Other comprehensive income	Equity Attributable to Controlling Shareholders	Non-controlling interest	Consolidated Equity
5.01	Opening balances	2,234,135	49,727	423,409	-	943	2,708,214	596	2,708,810
5.03	Adjusted opening balances	2,234,135	49,727	423,409	-	943	2,708,214	596	2,708,810
5.04	Transaction with shareholders	-	737	-	-	-	737	-	737
5.04.03	Granted options	-	737	-	-	-	737	-	737
5.05	Total comprehensive income	-	-	-	60,330	-	60,330	199	60,529
5.05.01	Net income for the period	-	-	-	60,330	-	60,330	203	60,533
5.05.02	Others comprehensive income	-	-	-	-	-	-	(4)	(4)
5.05.02.06	Non-controlling interest	-	-		-	-	-	(4)	(4)
5.06	Internal changes in equity	-	-	123	-	(314)	(191)	-	(191)
5.06.04	Depreciation of deemed cost	-	-	314	-	(314)	-	-	-
5.06.05	Additional dividends paid	-	-	(191)	-	-	(191)	-	(191)
5.07	Closing balances	2,234,135	50,464	423,532	60,330	629	2,769,090	795	2,769,885

Consolidated Quarterly Financial Information / Statement of Changes in Equity– 1/1/2013 to 6/30/2013

(R$ in thousands)

Code	Description	Paid-in Capital	Capital Reserve, Granted options and treasury shares	Income reserve	Retained earnings	Other comprehensive income	Equity Attributable to Controlling Shareholders	Non-controlling interest	Consolidated Equity
5.01	Opening balances	2,234,135	48,171	322,933	-	1,571	2,606,810	382	2,607,192
5.03	Adjusted opening balances	2,234,135	48,171	322,933	-	1,571	2,606,810	382	2,607,192
5.04	Transaction with shareholders	-	398	-	-	-	398	-	398
5.04.03	Granted options	-	398	-	-	-	398	-	398
5.05	Total comprehensive income	-	-	-	58,681	-	58,681	51	58,732
5.05.01	Net income for the period	-	-	-	58,681	(314)	58,681	51	58,732
5.06	Internal changes in equity	-	-	45	-	(314)	(269)	-	(269)
5.06.04	Depreciation of deemed cost	-	-	314	-	-	-	-	-
5.06.05	Additional dividends paid	-	-	(269)	-		(269)		(269)
5.07	Closing balances	2,234,135	48,569	322,978	58,681	1,257	2,665,620	433	2,666,053

Consolidated Quarterly Financial Information / Statement of Value Added

(R$ in thousands)

Code	Description	Accumulated current period 1/1/2014 to 6/30/2014	Accumulated previous period 1/1/2013 to 6/30/2013
7.01	Revenue	1,477,874	1,340,873
7.01.01	Sale of goods, products and services	1,476,878	1,338,952
7.01.02	Other revenue	1,080	1,991
7.01.04	(Reversal of) allowance for doubtful accounts	(84)	(70)
7.02	Inputs acquired from third parties	(700,101)	(638,048)
7.02.01	Cost of products, goods and services sold	(506,983)	(467,361)
7.02.02	Materials, energy, third-party services and others	(193,118)	(170,687)
7.03	Gross value added	777,773	702,825
7.04	Retentions	(85,894)	(79,559)
7.04.01	Depreciation, amortization and depletion	(85,894)	(79,559)
7.05	Net value added produced	691,879	623,266
7.06	Transferred value added received	39,255	34,467
7.06.02	Financial income	39,255	34,467
7.07	Total value added to be distributed	731,134	657,733
7.08	Distribution of value added	731,134	657,733
7.08.01	Personnel	333,145	295,817
7.08.02	Taxes, fees and contributions	177,648	168,824
7.08.03	Debt remuneration	159,808	134,360
7.08.04	Equity remuneration	60,533	58,732
7.08.04.03	Retained profits	60,330	58,681
7.08.04.04	Non-controlling interest	203	51

Comments on the Company’s Performance

To the shareholders

The second quarter of 2014 was negatively impacted by the 2014 FIFA World Cup due to fewer working days and our customers being focused on the event, which led many to postpone going to doctors or carrying out health exams.

We kept our focus on improving the quality of our services. This improvement process comprises investment in recruiting and training our professionals, in modernizing and expanding our technology park and increasing our capability to process exams in our central laboratories. The main activities carried out in the second quarter of 2014 are as follows:

- The Company, participated whith lecturers in major world events on radiology (*Jornada Paulista de Radiologia*, Magnetom World, International Society of Magnetic Resonance in Medicine, American Society of Neuroradiology)
- Central Laboratory in São Paulo (NTO) is recertified by the College of American Pathologists (CAP).
- Completion of a new Pathological Anatomy area within the Central Laboratory (NTO) in São Paulo.
- Renewal of the Toxicology and Analytical Chemistry technology park (mass spectrometer), and molecular biology (next generation sequencing).
- Completion of the conveyor first phase installation (full automation) at DF
- DASA physicians accounted for 48% of Brazilian production and 5% of world output of scientific papers presented at the American Association for Clinical Chemistry (AACC)

Gross operating income

The Company’s consolidated gross revenue for the second quarter of 2014 totaled R$ 743.8 million, representing a 6.5% increase against 2Q13, thus an adverse impact arising from the 2014 FIFA World Cup. For the six-month period of 2014, gross revenue amounted to R$ 1,476.9 million, a 10.3% increase when compared with the same period of 2013, when gross revenue totaled R$ 1,339.0 million.

Based on the Company’s gross revenue by service line, Lab-to-Lab market’ (examination processing service for third-party laboratories) had the best performance in the quarter, earning R$ 81.6 million and growing 10.8% against 2Q13 and representing 11.0% of Company’s total revenue. For the six-month period of 2014, revenue amounted to R$ 160.7 million, a 16.4% increase when compared with the same period of 2013, totaling 10.9% of the Company’s total revenue.

Revenue from outpatient market amounted to R$ 546.4 million, a 7.8% increase when compared with the second quarter of 2013 and totaling 73.5% of the Company’s total revenue. For the six-month period of 2014, revenue totaled R$ 1,085.9 million, an 11.0% increase when compared with the same period of 2013, totaling 73.5% of the Company’s total revenue.

Revenue from hospital market amounted to R$ 71.7 million, a 1.5% increase for the second quarter of 2014, thus representing 9.6% of the Company’s total revenue. For the six-month period of 2014, revenue was R$ 139.5 million, a 6.0% increase when compared with the same period of 2013, totaling 9.4% of the Company’s total revenue.

Revenue from public market amounted to R$ 44.1 million, a 6.7% decrease in the 2Q14, thus accounting for 5.9% of the Company's revenue. For the six-month period of 2014, revenue totaled R$ 90.8 million, a 0.3% decrease when compared with the same period of 2013, totaling 6.1% of the Company's total revenue.

Costs and gross profit

In the second quarter of 2014, costs of services totaled R$ 471.7 million, equivalent to 68.6% of net revenue, representing an increase of 8.9% against the second quarter of last year. In the second quarter of 2014, gross profit amounted to R$ 215.7 million, increasing 9.4% against the second quarter of last year.

For the six-month period of 2014, the cost of services rendered totaled R$924.0 million, representing 68.5% of net revenue, a 10.4% increase when compared with the same prior year period. Gross profit was R$ 425.6 million, a 13.1% increase when compared with the same prior year period.

Operating expenses

Operating expenses totaled R$ 140.3 million in the second quarter of 2014, representing 20.4% of net revenue. There was an increase of 13.0% against the second quarter of 2013, in which operating expenses represented 19.7% of net revenue. For the six-month period of 2014, operating expenses totaled R$ 283.9 million, representing 21.0% of net revenue, a 15.5% increase when compared with the same prior year period.
.

EBITDA

In the second quarter of 2014, EBITDA amounted to R$ 115.0 million, representing an increase of 3.8% against R$ 110.8 million in the second quarter of last year. For this quarter, EBITDA margin was of 16.7%, when compared with the 17.6% margin of the second quarter of last year. For the six-month period of 2014, we reached an EBITDA of R$ 227.6 million, representing an increase of 8.4% against R$209.9 million for the same prior year period.

In million of reais	*2Q14*	*2Q13*	*Δ%*	*YTD 2014*	*YTD 2013*	*Δ%*
Net income for the period	***31.9***	***35.2***	***-9,4%***	***60.5***	***58.7***	***3.1%***
(+) Income and social contribution taxes	*15.1*	*19.8*	*-23,5%*	*28.1*	*32.5*	*-13.7%*
(+) Net financial expenses	*28.4*	*18.1*	*57.0%*	*53.1*	*39.1*	*35.7%*
(+) Depreciation and amortization	*39.6*	*37.7*	*4.9%*	*85.9*	*79.5*	*8.0%*
EBITDA (R$ MM)	***115.0***	***110.8***	***3.8%***	***227.6***	***209.9***	***8.4%***
Ebitda margin	***16.7%***	***17.6%***	***-0.8 pa***	***16.9%***	***17.3%***	***-0.4 p.a***

Amounts in R$ (in thousands)	Six-month period ended 06/30/14	Second quarter 2014	Six-month period ended 06/30/13	Second quarter 2013
Income before income taxes	88,624	46,991	91,250	54,969
Adjustments:				
Depreciation and amortization (Cost)	54,335	26,099	52,103	24,280
Depreciation and amortization (General and administrative expenses)	31,559	13,493	27,432	13,459
Financial income (expenses)	53,054	28,441	39,094	18,100
EBITDA	227,572	114,994	110,809	209,879

Financial income (expenses)

In the second quarter of 2014, net financial expenses in the amount of R$ 28.4 million were recorded against R$ 18.1 million in the second quarter of 2013. The increase was due to the Central Bank Benchmark Rate (SELIC) and higher balance of short-term investments, due to funding from debentures occurred in October 2013. This funding also impacted costs referring to debentures/promissory notes.
In addition, in the second quarter of 2013, there was a positive impact of R$ 9.3 million as a result of a financial gain from joining the Special Tax Installment Payment Program of the State of São Paulo (PEP) of ICMS debts, whereas for this quarter the Company has been negatively impacted from financial discounts amounting to R$ 6.0 million.

For the six-month period of 2014, net financial expenses in the amount of R$ 53.1 million were accounted for against R$ 39.1 million in the same period of 2013.

Income and social contribution taxes

The income and social contribution taxes account totaled R$ 15.1 million for the quarter against R$ 19.8 million in the second quarter of last year. For the six-month of 2014, the taxes account accumulated R$ 28.1 million, against R$ 32.5 million in the same prior year period.

Net income

In the second quarter of 2014, net income totaled R$31.9 million, 9.4% lower than the R$35.2 million reported in the second quarter of last year. For the six-month period of 2014, net income totaled R$ 60.5 million, against R$ 58.7 million in the same prior year period, an increase of 3.1%.

Cash and cash equivalents and short-term investments

Cash and cash equivalents and short-term investments at the end of the quarter totaled R$497.6 million, allocated to: ensure the expansion and modernization of the existing units; open new units and replace imaging equipment; and improve the quality and payment of dividends.

Investments

In the second quarter of 2014, net investments in CAPEX amounted to R$ 35.2 million. From January to June 2014, investments totaled R$ 65.4 million. This year, investments will be particularly for: (i) implementing and developing production systems and supporting and renovating technology park, (ii) renovating and extending existing medical service units and new units, (iii) purchasing imaging equipment.

Indebtedness

Company's net debt totaled R$ 791.5 million in 2Q14. 66.8% of gross indebtedness is allocated to long term and 6.0% refer to foreign currency debts. Foreign currency debt mostly comprises bank loans and equipment financing. Domestic currency debts mostly refer to debentures.

Significant events for the quarter

The Board of Directors will await a decision - arbitration process

On April 23, 2014, the Company reported, in addition to the significant facts disclosed in the last few days, particularly those disclosed on March 7, 2014 about the filing, by Cromossomo Participações II S.A, of arbitration proceedings with the Market Arbitration Chamber of BM&FBOVESPA, that the Board of Directors decided to await a decision on such arbitration proceedings before taking any actions in addition to those taken so far about the matter in question.

Executive Vice President Administrative and Financial election

On April 25, 2014, the Board of Directors approved the election of Mr. Márcio Ramos Fernandes as Vice CFO, unified with the other members of the Executive Board, until the holding of the Annual Shareholders' Meeting that approves the accounts for the year ending December 31, 2015. He is liable for the finance, infrastructure, accounting, receivable, tax, controllership, treasury, information technology, supply, purchasing, import, third-party service and maintenance areas, in addition to those liabilities provided for in law.

On the same date, Mr. Octávio Fernandes, Executive Vice President Of Operations, became Executive Vice President of Clinical Analisys, who is liable for managing the product area that comprises products and services of the ancillary diagnosis service area (except for radiology imaging services and graphical methods), including operations of hospital technical centers and technical centers for production of diagnostic procedures for clinical analysis of various Company's Strategic Business Units, also liable for compliance with procedures and routines developed, pre- and post-analytical, in addition to quality controls, certificates, sustainability and internal processes, and for managing pathological anatomy, clinical research, medical relation, regulatory, logistics, storeroom and transportation areas.

Election of the Coordinator of the Audit Committee

Mr. Wander Rodrigues Teles was elected as Coordinator of the Company's Statutory Audit Committee ("CAE") in the Board of Directors' meeting held on March 24, 2014. Mr. Wander took his new position on May 6, 2014.

The Coordinator of CAE has recognized experience in corporate accounting matters, as provided for in paragraphs 5 and 6 of article 31-C of ICVM 308, as well as he complies with the independence requirement provided for in paragraph 2 of article 31-C of such order.

Transfer of treasury shares

On May 28, 2014, the Company communicated to its shareholders and the market in general that its Board of Directors approved, at a meeting held on May 27, 2014, the transfer of 106,576 treasury shares in private transactions, representing 0.034181% of the Company's capital stock, to the beneficiaries of the Company's First Stock Option Plan under the Option Plan to Purchase Shares approved by the Company's Special Shareholders' Meeting, held on January 5, 2011, due to the options exercised within the referred to First Program.

Decision on Public Civil Action

On June 26, 2014, the Company informed, in continuity to the Material Fact disclosed on October 29, 2012, and in accordance with CVM Rule No. 358, of January 3, 2002, that the Public Civil Action proposed by the Labor Prosecution Office of Rio de Janeiro, in connection with which it was summoned, along with its subsidiary Laboratórios Médicos Dr. Sérgio Franco Ltda., was dismissed at the lower court.

As previously disclosed, the referred to Public Civil Action questions, in general terms, the lawfulness of hiring medical companies specialized in the field of diagnostic support through imaging exams, requiring the hiring of physicians under the Brazilian Consolidated Labor Laws (CLT) regime and compensation for collective pain and suffering in the amount of R$ 20 million reais.

The 62nd Labor Court of Rio de Janeiro, in dismissing the claims by the Labor Prosecution Office of Rio de Janeiro, stated that "rendering of services by physicians to the defendants enjoy incompatible autonomy with the labor agreement".

The aforementioned decision may be subject matter of appeal by the Labor Prosecution Office. The Company has the conviction that, owing to its specific characteristics, the form of hiring that it is adopting is legal and strictly complies with applicable legal provisions, as well as supported by favorable case law in line with what it has disclosed and clarified in the Reference Form in items 4.1 and 4.3. As such, the Company will continue following this line of defense and taking the necessary measures.

Significant subsequent events

Merger of entities

On July 1, 2014, the Special Shareholders' Meeting unanimously and with no exceptions approved the merger of the Company's subsidiaries. (a) CDPI – Clínica de Diagnóstico por Imagem Ltda.; (b) Clínica de Ressonância e Multi-Imagem Ltda.; (c) Laboratórios Médicos Dr. Sergio Franco Ltda.; (d) Imagem e Diagnósticos Ltda.; (e) Multimagem PET Ltda.; and (f) Clínica de Ressonância e Multi-Imagem Caxias Ltda., with the consequent extinction of the entities merged, under the terms provided for in the Merger Protocol. The entities merged will be succeeded by the Company in all its rights and obligations, under the terms of article 227 of Law No. 6404/76 and article 1116 of the Brazilian Civil Code. Since the Company directly and indirectly holds total capital stock of the entities merged, (i) the Company will not increase capital nor issue new shares as a result of the merger, (ii) it is exempt from preparation of valuation report at market value as mentioned in article 264 of Law No. 6404/76, since the Company had already been exempted from compliance with this requirement by the Securities and Exchange Commission (CVM), and (iii) there will be no right to withdraw from the company due to the merger.

CADE Judgment – Cromossomo Participações II S/A

In a judgment session held on July 16, 2014, the Brazil's Administrative Council for Economic Defense (CADE) approved the acquisition by Cromossomo Participações II S/A of common shares issued by the Company, as a result of which Edson de Godoy Bueno and Dulce Pugliese de Godoy Bueno (shareholders owning, indirectly, all of the capital stock of Cromossomo), will control, directly and indirectly, more than 70% of the Company's capital stock, pursuant to Concentration Act No. 08700.002372/2014-07. Such approval by CADE was conditional upon compliance with an Agreement on Control of Concentrations (ACC).

The ACC is the equivalent mechanism under current antitrust law (Law No. 12529/11), as the old Performance Commitment Instrument applicable under Law No. 8884/94. Furthermore, according to information disclosed by CADE, the ACC obliges Cromossomo's shareholders to formally adhere to the obligations that had been provided for in the Performance Commitment Instrument the Company executed with CADE, in the official papers for Concentration Act nº 08012.010038/2010-4, which analyzed the association of DASA, MD1 Diagnósticos S.A. and others, as reported in a Material Fact notice disclosed by the Company on December 4, 2013.

The Company has not had access to any information other than that posted by CADE on the following link: http://www.cade.gov.br/Default.aspx?1427f70110051b18e250e373cf74

Change of Board of Directors members and Statutory Audit Committee

On July 24, 2014, the Board of Directors considered the request of resignation presented to the Company on July 17, 2014, by Mr. Mauricio Bittencourt Almeida Magalhaes, from the position of member of the Board of Directors to which he was elected at the Annual Shareholders' Meeting held on April 22, 2013, to hold office until the meeting to consider the closing balance sheet for 2014. On the same date, the Board of Directors approved the appointment of Marcelo Noll Barboza as a substitute for the position of Board of Directors member previously held by Maurício Bittencourt Almeida Magalhães, under the terms of paragraph 3, article 18 of the Company's Articles of Incorporation and article 150 of the Brazilian Corporation Law.

On the same date, the Board of Directors also considered the request of resignation presented in the letter dated July 17, 2014, to the position of member of CAE to which he was elected at the Board of Director' Meeting held on April 22, 2013, and elected Marcelo Noll Barboza to substitute him, as a member with no specific denomination, for term of office up to April 21, 2023 – together with other CAE members.

Resignation and election of Directors

On July 24, 2014, the Board of Directors accepted Marcelo Rucker's request of resignation from the position of People Director, which will be extinguished. On the same date, Adriano Brito da Costa Lima was elected to the position of Vice-Chairman of Human Resources with the same powers previously assigned to the People Director, and Lilian Cristina Pacheco Lira to the position of Director of Risk Management, Compliance and Internal Control, to be held jointly with the position of Legal Director. Her attributions will comprise those addressed by law as well as to direct, manage, coordinate and supervise the area of risk management, compliance and internal controls, under a unified term of office with the other members of the Board until the Annual Shareholders' Meeting approving the accounts for fiscal year ending December 31, 2015.

The Vice Chairman of Human Resources will occupy the position of member of the Company's People Committee replacing Marcelo Rucker to fulfill his term of office until the Annual Shareholders' Meeting examining the financial statements for 2014, the reelection of which is allowed and may be extended up to the inauguration of their respective successors.

Perspectives for 2014

This year, the Company is increasing the number of opening of new units and the expansion of existing units so as to increase its capacity and quality of services.

We will continue to intensify the relationship with physicians through seminars, visits and events in order to promote the exchange of ideas and knowledge of our physicians. With the purpose of increasing the perceived quality of our services, we will continue researching and creating techniques and studies that promote knowledge.

We effected the merger of the MD1 companies, which will bring operating and tax synergies for the second quarter of 2014. We continue investing in the modernization of existing units, opening of new units, replacement of imaging equipment, together with greater investment to improve the quality of operations, will enable an environment more favorable to growth, based on the earnings for this year.

Projections and non-accounting data

The statements contained in this document, referring to business perspectives, projections on operating outcomes, financial income (expenses), and those related to the Company's expected growth, are only projections and, as such, based solely on Management's expectations for the future of the Company's businesses. This performance report includes accounting and non-accounting data, such as: operating and financial data, and projections based the Management’s expectations. Non-accounting data were not subject to audit by the Company's independent auditors.

Representation of the Executive Board

Observing the provisions of CVM Ruling No. 480, we represent that we have discussed, reviewed and agreed with the quarterly information and with the independent auditor’s review report issued on the respective quarterly information for the period ended June 30, 2014.

Acknowledgements

We thank our employees for their commitment, effort and talent, which enable us to obtain promising results and thank our customers and shareholders for their trust.

Notes to Quarterly Information

1. Operations

Diagnósticos da América S/A (Company) is a publicly-held corporation located in the city of Barueri, São Paulo State, with its registration granted by the Brazilian Securities Commission (CVM) for the trading of its securities on the stock market on November 5, 2004, and has been listed on the Novo Mercado segment of Bovespa since November 19, 2004, under code DASA3.

The Company's business purpose is to render services directly to individuals or through health insurance plans, insurance companies, medical-hospital assistance entities, other entities for healthcare financing, in the following areas: (i) clinical analysis, directly or through contracted laboratories; and (ii) other auxiliary diagnostic support services (SAD), exclusively through specialized clinics, as, for instance, in the following areas: a) cytology and pathologic anatomy; b) diagnostic by imaging and graphic methods; and c) nuclear medicine. As Management does not control them separately in their business process, they are not being recognized as reportable segments.

In addition, it explores activities related to: (i) tests in food and substances to evaluate risks for the human being; (ii) import, for its own use, of medical-hospital equipment, sets for diagnostics and related material in general; (iii) preparation, edition, publishing and distribution of newspapers, books, magazines, periodicals and other written media on scientific researches and activities developed by the Company; (iv) granting and administration of business franchising including advertising and publishing fund, training and selection of labor, supplying of equipment and research material suppliers, among others. The Company operates in lab-to-lab business (support to laboratories) through the Álvaro brand, and began offering services in the public health sector through the CientíficaLab brand. The Company can also hold equity interest in other entities.

Notes to Quarterly Information

The Company ended the first six-month period of 2014 with 521 operating units, ambulatory and hospital:

Brands	State	6/30/2014	12/31/2013
Delboni Auriemo (i)	São Paulo	**43**	42
Lavoisier	São Paulo	**76**	77
Bronstein	Rio de Janeiro	**41**	41
Lâmina (i)	Rio de Janeiro	**14**	14
Pasteur	Brasília	**25**	25
Frischmann	Paraná	**38**	39
Image	Bahia	**4**	4
Laboratório Álvaro	Paraná	**14**	14
LabPasteur	Ceará	**18**	17
Vita-Lâmina	Santa Catarina	**2**	2
Atalaia	Goiás	**22**	22
Exame	Brasília	**22**	23
MedImagem	Rio de Janeiro	**7**	7
Hospital Mãe de Deus	Rio Grande do Sul	**3**	3
Cedic/Cedilab	Mato Grosso	**10**	9
Unimagem	Ceará	**1**	1
CERPE	Pernambuco	**37**	37
Sérgio Franco	Rio de Janeiro	**80**	80
Proecho	Rio de Janeiro	**15**	15
Multi Imagem	Rio de Janeiro	**6**	6
CDPI	Rio de Janeiro	**7**	7
Previlab	São Paulo	**19**	18
Cytolab	São Paulo	**14**	13
Alta Excelência Diagnóstica – *Premium*	São Paulo and Rio de Janeiro	**3**	3
		521	519

(i) At June 30, 2014, the brand Club DA had 23 units, 19 of them linked to the brand Delboni Auriemo and 4 units linked to the brand Lâmina.

In addition, CientificaLab operates in the public healthcare segment, and the revenue arises from agreements entered into with customers in this segment. This operation ended the first six-month period of 2014 with 29 clients, with exam requisitions totaling 1.6 million. CientificaLab has 589 collection units, 64 of them are hospitals and 525 ambulatory are Outpatient clinics not related to the units listed above.

The information above is not comprised by the scope of the independent auditors.

Notes to Quarterly Information

2. Performance Commitment Agreement ("PCA")

At the trial session held on December 4, 2013, Merger Review Process No. 08012.010038/2010 was approved by CADE Administrative Court, under the terms of Reporting Member, with restrictions negotiated with the Company and formalized by means of the Performance Commitment Agreement ("PCA").

With the execution of PCA, the Transaction Reversibility Preservation Agreement ("APRO") executed by the Company on October 26, 2011, CADE considered this as completed, extinct and replaced by PCA, as it accomplished the objective of preserving the transaction reversibility nature.

Restrictions provided for by PCA are as follows:

(i) The Company shall dispose assets in the cities located in the state of Rio de Janeiro, jointly totaling R$ 110,000 of the revenue for the year for a single acquiring third party which (a) has no direct or indirect relationship with the Company; and (b) does not have more than 20% (twenty percent) of the relevant market of Medical Diagnosis Services ("M DS") in the city of Rio de Janeiro;

(ii) the Company, for the initial term of 3 (three) years, cannot conduct the operations described in items (a) to (c) below, involving MDS service providers in the cities of Duque de Caxias, Nilópolis, Niterói, Nova Iguaçu, Rio de Janeiro, São Gonçalo and Belford Roxo, in the relevant markets of: (a) clinical analysis, (b) pathology and cytopathology, (c) echocardiography, echocardiography, Doppler, ecovascular, Eco carotid and vertebral ecotransesophageal, (d) EEG, (e) CT (f) ultrasonography, (g) MRI, (h) bone densitometry and (i) mammogram:

   (A) Merger or acquisition of company operating in MDS market ("merger/acquisition");

   (B) Direct or indirect acquisition, by purchase or exchange of shares, units of interest or securities convertible into shares, or tangible or intangible assets through contract or by any other mean, of the control or portion of one or more companies operating in the Medical Diagnosis Services ("MDS") market; or

   (C) execution of an association contract, consortium or joint venture with companies in the MDS market ("Association" and, together with merger/acquisition transactions, as defined above, "Qualifying Operations").

(iii) the Company cannot perform, for the initial term of 2 (two) years, any of the Qualifying Operations involving MDS companies in the cities of Guarulhos, Osasco, Santo André, São Bernardo do Campo, São Caetano do Sul, São Paulo and Taboão da Serra, in relevant markets of: (a) clinical analysis, (b) pathology and cytopathology (c) echocardiography, echocardiography, Doppler, eco-vascular, eco-carotid, vertebral, and eco-transesophageal, (d) CT scan, (e) MRI, and (f) ultrasonography;

(iv) the Company cannot perform, for the initial term of 2 (two) years, any of the Qualifying Operations involving MDS companies in the cities of Curitiba and São José dos Pinhais, in the relevant markets of: (a) clinical analysis, (b) CT and (c) ultrasonography;

Notes to Quarterly Information

(v) after the initial three-year or two-year term, as the case may be, as determined in items (ii), (iii) and (iv) above, respectively, and for the additional term of two years after the initial term, the Company shall submit any Qualifying Operations to prior approval from CADE in the respective locations, even if the minimum billing standards provided by competition law for mandatory notification of merger procedures are not reached.

Observing the restrictions described above, MDS a) does not hinder the Company's, or any of its subsidiaries', corporate restructuring operations, either directly or indirectly; b) does not hinder acquisition of companies outside the cities mentioned above; and c) does not have provisions that may hinder the Company's organic growth.

The public version of Reporting Member, which influenced the decision of CADE Administrative Court, and exposes reason considered by CADE for the adopted decision, is available at www.cade.gov.br, as well as on the Company's investor relations website (www.dasa3.com.br).

Company management is carrying out the necessary actions to timely fulfil the obligations determined by CADE within TCD.

Notes to Quarterly Information

3. Consolidation procedures

The quarterly financial information comprises the financial information of the Company and the following subsidiaries:

Direct Subsidiaries	Interest	06/30/14	12/31/13
CDPI – Clínica de Diagnóstico por Imagem Ltda.	Diagnósticos da América S.A.	**99.99%**	99.99%
	Laboratórios Médicos Dr. Sérgio Franco Ltda.	**0.01%**	0.01%
Cientificalab Produtos Laboratoriais e Sistemas Ltda.	Diagnósticos da América S.A.	**75.95%**	75.95%
	DASA Real Estate Empreendimentos Imobiliários Ltda.	**24.05%**	24.05%
Clínica de Ressonância e Multi Imagem Ltda.	Diagnósticos da América S.A.	**99.99%**	99.99%
	Laboratórios Médicos Dr. Sérgio Franco Ltda.	**0.01%**	0.01%
Dasa Centro Oeste Participações Ltda.	Diagnósticos da América S.A.	**99.00%**	99.00%
	DASA Real Estate Empreendimentos Imobiliários Ltda.	**1.00%**	1.00%
Dasa Finance Corporation	Diagnósticos da América S.A.	**100.00%**	100.00%
Dasa Log Empreendimentos Ltda.	Diagnósticos da América S.A.	**99.00%**	99.00%
	DASA Real Estate Empreendimentos Imobiliários Ltda.	**1.00%**	1.00%
Dasa Nordeste Participações Ltda.	Diagnósticos da América S.A.	**99.00%**	99.00%
	DASA Real Estate Empreendimentos Imobiliários Ltda.	**1.00%**	1.00%
Dasa Real Estate Empreendimentos Imobiliários Ltda.	Diagnósticos da América S.A.	**99.99%**	99.99%
	Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda.	**0.01%**	0.01%
Dasa Sudoeste Participações Ltda.	Diagnósticos da América S.A.	**99.00%**	99.00%
	DASA Real Estate Empreendimentos Imobiliários Ltda.	**1.00%**	1.00%
Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda.	Diagnósticos da América S.A.	**99.00%**	99.00%
	Dr. Luciano Flávio Freitas de Almeida	**1.00%**	1.00%
Dasa Property Participações Ltda.	Diagnósticos da América S.A.	**99.00%**	99.00%
	DASA Real Estate Empreendimentos Imobiliários Ltda.	**1.00%**	1.00%
Laboratórios Médicos Dr. Sérgio Franco Ltda.	Diagnósticos da América S.A.	**99.99%**	99.99%
	CDPI – Clínica de Diagnóstico por Imagem Ltda.	**0.01%**	0.01%
Previlab Análises Clínicas Ltda.	Diagnósticos da América S.A.	**99.55%**	99.55%
	Alcione Moya Aprilante	**0.39%**	0.39%
	César Antônio Blázio	**0.06%**	0.06%
Pro Echo Cardiodata Serviços Médicos Ltda.	Diagnósticos da América S.A.	**69.58%**	69.58%
	Laboratórios Médicos Dr. Sérgio Franco Ltda.	**30.42%**	30.42%
LAFÊ Serviços Diagnósticos Ltda.	Diagnósticos da América S.A.	**99.98%**	99.98%
	Pro Echo Cardiodata Serviços Médicos Ltda.	**0.01%**	0.01%
	CDPI – Clínica de Diagnóstico por Imagem Ltda.	**0.01%**	0.01%

Notes to Quarterly Information

Indirect subsidiaries	Interest	06/30/14	12/31/13
Check Up UP – Unidade Preventiva, Diagnóstico e Medicina Preventiva Ltda.	CDPI – Clínica de Diagnóstico por Imagem Ltda.	**99.99%**	99.99%
	Laboratórios Médicos Dr. Sérgio Franco Ltda.	**0.01%**	0.01%
Clínica de Ressonância e Multi Imagem Caxias Ltda.	Clínica de Ressonância Multi Imagem Ltda.	**99.99%**	99.99%
	Laboratórios Médicos Dr. Sérgio Franco Ltda.	**0.01%**	0.01%
Clínica de Ressonância e Multi Imagem Petrópolis Ltda.	Clínica de Ressonância Multi Imagem Ltda.	**70.00%**	70.00%
	José Antonio Fragoso Borges Filho	**15.00%**	15.00%
	José Carlos de Castro Bersot	**7.50%**	7.50%
	Eduardo Luiz Primo de Siqueira	**7.50%**	7.50%
Imagem e Diagnóstico Ltda.	CDPI – Clínica de Diagnóstico por Imagem Ltda.	**99.99%**	99.99%
	Laboratórios Médicos Dr. Sérgio Franco Ltda.	**0.01%**	0.01%
Multimagem PET Ltda.	CDPI – Clínica de Diagnóstico por Imagem Ltda.	**99.99%**	100.00%
	Imagem e Diagnósticos Ltda.	**0,01%**	0,00%
Stat Análises Clínicas Ltda.	Previlab Análises Clínicas Ltda.	**99.66%**	99.66%
	Alcione Moya Aprilante	**0.17%**	0.17%
	César Antônio Blázio Sanches	**0.17%**	0.17%
Pro Echo Cardiodata Serviços Médicos Ltda.	Diagnósticos da América S.A.	**69.58%**	69.58%
	Laboratórios Médicos Dr. Sérgio Franco Ltda.	**30.42%**	30.42%
Incebrás Instituto Brasileiro da Coluna e do Cérebro Ltda.	CDPI – Clínica de Diagnóstico por Imagem Ltda.	**29.00%**	29.00%
	Jorge Alberto Costa e Silva	**70.00%**	70.00%
	Romeu Côrtes Domingues	**1.00%**	1.00%

Notes to Quarterly Information

4. Basis for preparation of quarterly financial information

4.1. Statement of compliance (with respect to IFRS and CPC standards)

The quarterly financial information includes:

- The consolidated quarterly financial information prepared in accordance with CPC 21 (R1) and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).
- The Company's individual quarterly financial information prepared in accordance with CPC 21 (R1) - Interim Financial Reporting and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).

The issuance of the individual and consolidated quarterly financial information was authorized by the Board of Directors at the meeting held on August 11, 2014.

4.2. Basis for measurement

The individual and consolidated quarterly financial information were prepared on the basis of historical cost, with except for the following items recognized in the statement of financial position: derivative financial instruments measured at fair value; and (ii) non-derivative financial instruments measured at fair value thought profit or loss.

4.3. Functional and reporting currency

The preparation of the individual and consolidated quarterly financial information in accordance with IFRS and CPC standards requires Management to make judgments, estimates and assumptions that may affect the application of accounting policies and the reported values of assets, liabilities, revenue and expenses.

4.4. Use of estimates and judgment

The preparation of the individual and consolidated quarterly financial information in accordance with IFRS and with accounting practices adopted in Brazil requires Management to make judgments, estimates and assumptions that may affect the application of accounting policies and the reported values of assets, liabilities, revenue and expenses. Actual results may differ from such estimates.

Estimates and assumptions are permanently reviewed. Reviews relating to accounting estimates are recorded in the period in which the estimates are reviewed, as well as in any other future periods affected.

Uncertainties about the assumptions or estimates that may pose significant risks of material adjustments in future periods are detailed in the following notes:

Notes to Quarterly Information

- Note 5.8 – Impairment – mainly assumptions used in discounted cash flow estimates used for calculation of goodwill impairment;
- Note 9 - Trade accounts receivable, analysis of allowance for doubtful accounts;
- Note 19 - Provision for tax, social security, labor and civil risks;
- Note 21 – Income and social contribution taxes – deferred tax recovery analysis; and
- Note 24 – Assumptions used for determining the fair value of financial instruments.

5. Significant accounting practices

The Company represents that the Quarterly Financial Information (ITR) are presented in accordance with the accounting practices presented in Note 5 to the financial statements for the year ended December 31, 2013.

Many accounting practices and disclosures of the Company require the determination of fair value for financial and nonfinancial assets and liabilities. Fair value has been determined for measurement and/or disclosure purposes based on the methods disclosed in Note 6 to the financial statements for the year ended December 31, 2013 and should be reviewed together with these statements. If applicable, additional information on the assumptions used in determining fair value is disclosed in specific notes of the respective assets or liabilities.

Therefore, this quarterly financial information should be read jointly with the financial statements for the year ended December 31, 2013.

6. IFRS and CPC pronouncements and new legal requirements

6.1. New pronouncements that entered into force on January 1, 2014, but did not significantly impact the Company.

i) IAS 32 - Offsetting Financial Assets and Financial Liabilities - Amendments to IAS 32 - These amendments clarify the meaning of “currently has a legally enforceable right to set off the recognized known amounts” and the criterion that would cause settlement mechanisms that are not simultaneous (such as clearing house systems) to qualify for such offsetting.

ii) Investment Entities (Amendments to IFRS 10, IFRS 12 and IAS 27) - These amendments introduce a consolidation exception for entities that meet the definition of ‘investment entity’ in IFRS 10. Under this exception, investment entities are required to measure their investments in subsidiaries at fair value through profit or loss.

iii) IAS 39 - Novation of Derivatives and Continuation of Hedge Accounting - Amendments to IAS 39 - These amendments introduce an exception to the requirement to discontinuance of hedge accounting where a derivative, which is designated as hedging instrument, met certain conditions. The Company's policies not to act with derivative financial instrument transactions.

Notes to Quarterly Information

iv) IFRIC 21 – Levies – It clarifies that an entity recognizes a liability for a levy when the activity that triggers payment, as identified by the relevant legislation, occurs. For a levy that is triggered upon reaching a given metric, the interpretation indicates that no liability should be recognized before the specified metric is reached.

6.2. New pronouncement that will be effective for annual periods beginning on or after January 1, 2015

i) IFRS 9 - Financial Instruments - It reflects the first phase of IASB's project to replace IAS 39 and applies to classification and measurement of financial assets and liabilities as defined by IAS 39. Initially, the pronouncement would become effective for annual periods beginning on or after January 1, 2013, but Amendments to IFRS 9: Mandatory Effective Date and Transition Disclosures, issued in December 2011, amended the effective date of IFRS 9 to annual periods beginning on or after January 1, 2015. In the subsequent phases, IASB will tackle issues such as hedge accounting and provision for impairment of financial assets. The Company does not expect that such standard causes a significant impact on its quarterly financial information.

There are no other IFRS standards that are not yet into effect that may significantly impact the Company.

6.3. Provisional Executive Order No. 627 converted into law

In November 2013, Provisional Executive Order No. 627 was published and established that no taxation should be levied on profits and dividend calculated based on P&L computed between January 1, 2008 and December 31, 2013, by legal entities adopting the taxable profit, profit computed as a percentage of the Company's gross revenue, or arbitrated profit determined by the tax authorities, effectively paid through the publication date of the referred to Provisional Executive Order, at amounts exceeding those computed in light of the accounting methods and criteria in force as of December 31, 2007, provided that the taxpayer that has paid profit and dividend elected early adoption of the new tax regime as from 2014.

In May 2014, this Provisional Executive Order was converted into Law No. 12973, with amendment to some provisions of MP 672, including in connection with how to treat profits, dividend, interest on equity and investment measurement at equity pickup. Differently from the Provisional Executive Order, Law No. 12973 determined that no taxes are to be levied, unconditionally, on profit and dividend calculated based on P&L computed from January 1, 2008 to December 31, 2013.

The Company and its subsidiaries prepared studies on the effects that might arise from the application of Law No. 12973 provisions, and concluded that there are no material effects on its quarterly financial information as of June 30, 2014 and financial statements of December 31, 2013. The Company is assessing whether to elect early adoption of effects, and a decision will be expressed in the Federal Tax Debt and Credit Return (DCTF), regarding the triggering events occurring in the month of August 2014.

Notes to Quarterly Information

7. Cash and cash equivalents

	Company		Consolidated	
	6/30/2014	**12/31/2013**	**6/30/2014**	**12/31/2013**
Cash and banks	**11,158**	14,826	**32,424**	20,868
Marketable securities	**227,148**	471,745	**409,397**	515,013
	238,306	486,571	**441,821**	535,881

Cash and cash equivalents classified in consolidated current assets are presented below:

	6/30/2014		12/31/2013	
	Amount	**Average yield for the period**	**Amount**	**Average yield for the year**
Cash and banks	**32,424**	-	20,868	-
Bank Deposit Certificate (CDB) / Repurchase agreements	**235,041**	**102.97% of CDI**	397,610	102.19% of CDI
Fixed income fund	**174,356**	**101.24% of CDI**	117,403	102.36% of CDI
	441,821		535,881	

Bank deposits represent balances in banks and immediate liquidity rights of which the use is not subject to any restrictions.

Marketable securities are readily redeemable from the issuer into a known cash amount and are subject to insignificant risk of change in value.

Notes to Quarterly Information

8. Marketable securities

		Company			
		6/30/2014		12/31/2013	
	Currency	Amount (R$)	Average yield for the period	Amount (R$)	Average yield for the year
CDB / Repurchase agreements **(a)**	R$	**6,629**	**102.97% of CDI**	6,393	100.01 of CDI
Fixed income fund **(a)**	R$	**17,633**	**101.24% of CDI**	19,791	102.25% of CDI
Noncurrent assets		**24,262**		26,184	

		Consolidated					
		6/30/2014			12/31/2013		
	Currency	Amount (US$)	Amount (R$)	Average yield for the period	Amount (US$)	Amount (R$)	Average yield for the year
CDB / Repurchase agreements **(a)**	R$	**-**	**8,652**	**102.97% of CDI**	-	8,316	100.01% of CDI
Fixed income fund **(a)**	R$	**-**	**27,732**	**101.24% of CDI**	-	29,477	102.25% of CDI
Corporate bonds **(b)**	US$	**25,345**	**55,822**	**3.57% p.a.**	31,153	72,980	4.63% p.a.
			92,206			110,773	
Current assets			**(55,822)**			(72,980)	
Noncurrent assets			**36,384**			37,793	

(a) The consolidated amount of R$36,384 (R$37,793 at December 31, 2013) invested in fixed income funds and CDB / Committed transactions corresponds to guarantee for payment of contingencies that may be demanded from acquired companies, for a period of up to 6 years from the date of acquisition.

(b) Securities private companies acquired by subsidiary abroad.

Notes to Quarterly Information

9. Trade accounts receivable

	Company		Consolidated	
	6/30/2014	**12/31/2013**	**6/30/2014**	**12/31/2013**
Trade notes receivable:				
Falling due	**255,055**	237,123	**395,041**	330,558
Amounts overdue **(b)**	**131,124**	127,425	**212,524**	187,579
	386,179	364,548	**607,565**	518,137
Other accounts receivable:				
Checks receivable	**345**	456	**696**	795
Bounced check	**865**	808	**1,543**	1,469
Credit card	**11,320**	15,135	**12,260**	15,916
Unbilled health plans **(a)**	**56,401**	55,526	**91,685**	103,371
	68,931	71,925	**106,184**	121,551
Total receivable:	**455,110**	436,473	**713,749**	639,688
Deducted of:				
Allowance for doubtful accounts due to disallowance, default and returned checks	**(44,278)**	(46,318)	**(68,170)**	(67,486)
Adjustment to present value	**-**	-	**(1,091)**	-
	410,832	390,155	**644,488**	572,202
Current assets	**(410,118)**	(389,860)	**(639,582)**	(566,262)
Noncurrent assets	**714**	295	**4,906**	5,940

(a) Refers to amounts of services rendered and not yet billed until to the closing of the period. Services not billed within 120 days are written off from account Agreements to be billed, adjusting profit or loss for the corresponding period.

Notes to Quarterly Information

(b) The aging of overdue balances is presented below:

		Company					
		6/30/2014			12/31/2013		
	%	Gross amount	Provision for loss	Net amount	Gross amount	Provision for loss	Net amount
0 to 30		**41,098**	**-**	**41,098**	37,685	-	37,685
31 to 60		**16,504**	**-**	**16,504**	14,851	-	14,851
61 to 90		**10,539**	**-**	**10,539**	11,914	-	11,914
91 to 120	25%	**10,359**	**(2,590)**	**7,770**	6,957	(1,739)	5,218
121 to 180	50%	**10,277**	**(5,139)**	**5,138**	12,536	(6,268)	6,268
181 to 360	75%	**26,647**	**(19,984)**	**6,662**	23,918	(17,939)	5,979
Over 360	100%	**15,700**	**(15,700)**	**-**	19,564	(19,564)	-
		131,124	**(43,413)**	**87,711**	127,425	(45,510)	81,915
Returned checks		**865**	**(865)**	**-**	808	(808)	-
		131,989	**(44,278)**	**87,711**	128,233	(46,318)	81,915

		Consolidated					
		6/30/2014			12/31/2013		
	%	Gross amount	Provision for loss	Net amount	Gross amount	Provision for loss	Net amount
0 to 30		**70,653**	**-**	**70,653**	52,629	-	52,629
31 to 60		**25,220**	**-**	**25,220**	22,667	-	22,667
61 to 90		**20,158**	**-**	**20,158**	18,091	-	18,091
91 to 120	25%	**17,104**	**(4,276)**	**12,828**	13,513	(3,378)	10,135
121 to 180	50%	**17,699**	**(8,850)**	**8,850**	17,964	(8,982)	8,982
181 to 360	75%	**32,752**	**(24,563)**	**8,188**	36,232	(27,174)	9,058
Over 360	100%	**28,938**	**(28,938)**	**-**	26,483	(26,483)	-
		212,524	**(66,627)**	**145,897**	187,579	(66,017)	121,562
Returned checks		**1,543**	**(1,543)**	**-**	1,469	(1,469)	-
		214,067	**(68,170)**	**145,897**	189,048	(67,486)	121,562

The collection process for diagnostic support services provided by the Company is complex due to a variety of factors, including the large number of health plans used and different coverage offered. This complexity has historically given rise to loss due to disallowances. To a lesser extent, there are also losses due to default.

Disallowances mainly refer to: (i) operating issues, such as services rendered to customers of health care plans without previous authorization; (ii) sales issues, such as new price lists agreed, which have not been updated on both systems; and (iii) technical issues, such as different interpretations of examination requisitions.

Notes to Quarterly Information

To cover the losses as a result of such disallowances and default, the Company adopts the policy of recording a provision for losses from disallowances and default based on receivables overdue for more than 90 days, as shown below:

Overdue receivables	% of provision
91 and 120 days	25%
121 and 180 days	50%
181 and 360 days	75%
Above 360 days	100%

For this six-month period, losses arising from disallowance and default represented 2.5% of gross operating revenue (3.4% in the second quarter of 2013).

From 2012 onwards, the Company started to write-off trade notes overdue for more than 2 years against provision. Accordingly, in the first quarter of 2014, R$ 9,668 (R$ 34,720 in the first quarter of 2013) were written off.

The Company also records provisions for all bad checks, corresponding to, at June 30, 2014, R$ 865 (R$ 808 at December 31, 2013) in Company and to R$ 1,543 (R$ 1,469 at December 31, 2013) in Consolidated.

Given that receivables from credit cards companies are historically fully paid, the Company has not set up an allowance for losses in this account.

Changes in allowances for doubtful accounts due to disallowance, default and returned checks due to insufficient funds, for 2014 second quarter in consolidated, is as follows:

Balance at December 31, 2013		(67,486)
Change in consolidated provision		
Allowance for doubtful accounts due to disallowance and default	(37,325)	**(a)**
Reversal of allowance for disallowance and default due to payment and resources proper disallowance	27,047	
Derecognition of provision for receivables overdue for more than 2 years	9,668	
Reversal of provision for returned checks	(74)	
Net changes of provisions		(684)
Balance at June 30, 2014		(68,170)

(a) Loss in 2014 first semester, as disclosed in Note 27.

Notes to Quarterly Information

10. Inventories

	Company		Consolidated	
	6/30/2014	12/31/2013	6/30/2014	12/31/2013
Direct material - domestic	**24,142**	23,643	**39,423**	35,406
Direct material – imported	**5,386**	5,593	**8,131**	7,664
Secondary material – domestic	**9,370**	7,857	**14,427**	11,496
Supplies	**4,387**	3,881	**6,700**	5,836
Provision for obsolescence	**(241)**	(568)	**(728)**	(1,019)
	43,044	40,406	**67,953**	59,383

11. Taxes recoverable

	Company		Consolidated	
	6/30/2014	12/31/2013	6/30/2014	12/31/2013
Income and social contribution taxes (IR/CS) – withholding income tax	**6,103**	6,911	**12,853**	10,607
IR/CS – prepaid amounts of the period	**-**	-	**2,154**	-
IR/CS – credits recoverable	**66,668**	63,222	**84,303**	83,861
Contribution Tax on Gross Revenue for Social Integration Program (PIS) and Contribution Tax on Gross Revenue for Social Security Financing (COFINS) – withholding income tax	**19,542**	19,437	**28,761**	27,214
Service Tax (ISS) -withholding income tax	**5,122**	5,385	**13,348**	13,653
National Institute for Social Security (INSS) recoverable	**7,033**	6,089	**29,543**	27,502
Other	**6,704**	6,255	**7,312**	6,859
	111,172	107,299	**178,274**	169,696

Notes to Quarterly Information

12. Investments

12.1 - Information on investments in subsidiaries

	Company		Consolidated	
	6/30/2014	**12/31/2013**	**6/30/2014**	**12/31/2013**
DASA Real Estate Empreendimentos Imobiliários Ltda.	**29,038**	29,733	**-**	-
CientificaLab Produtos Laboratoriais e Sistemas Ltda	**83,384**	85,981	**-**	-
Instituto de Endocrinologia e Medicina Nuclear do Recife S.A. (CERPE)	**37,196**	33,543	**-**	-
CDPI - Clínica de Diagnóstico por Imagem Ltda.	**85,882**	47,368	**-**	-
CRMI - Clínica de Ressonância e Multi Imagem Ltda.	**16,511**	16,102	**-**	-
Pro Echo Cardiodata Serviços Médicos Ltda.	**88,711**	88,079	**-**	-
Laboratórios Médicos Dr. Sérgio Franco Ltda.	**153,048**	122,884	**-**	-
Previlab - Analises Clinicas Ltda.	**33,817**	25,813	**-**	-
DASA Finance Corporation	**5,842**	2,795	**-**	-
LAFÊ Serviços Diagnósticos Ltda.	**6,107**	-		
Dasa Property Participações Ltda.	**52**	52	**-**	-
Dasa Nordeste Participações Ltda	**51**	51	**-**	-
Dasa Centro Oeste Participações Ltda.	**51**	51	**-**	-
Dasa Sudoeste Participações Ltda.	**51**	51	**-**	-
	539,741	452,503	**-**	-
Other investments	**643**	624	**855**	786
	540,384	453,127	**855**	786

Notes to Quarterly Information

Subsidiary	Subsidiary	Reporting date	Number of units of interest/ shares	Number of unites of interest/ shares held	Interest in paid-in capital (%)	Paid-in capital	Profit for the period
DASA Real Estate	6/30/2014	25,667,079	25,667,078	99.99	25,667	29,038	(695)
	12/31/2013	25,667,079	25,667,078	99.99	25,667	29,733	(836)
CientíficaLab	6/30/2014	70,676,629	53,676,628	75.95	70,677	83,384	(2,597)
	12/31/2013	70,676,629	53,676,628	75.95	70,677	85,981	(12,536)
DASA Finance Corp	6/30/2014	50,000	50,000	100	41,123	5,842	3,047
	12/31/2013	50,000	50,000	100	41,123	2,795	(12,117)
CERPE	6/30/2014	122,024	120,804	99.00	122	37,196	4,614
	12/31/2013	122,024	120,804	99.00	122	33,543	4,544
CDPI	6/30/2014	1,834,280	1,834,279	99.99	54,843	85,882	7,244
	12/31/2013	1,834,280	1,834,279	99.99	18,343	47,368	8,909
CRMI	6/30/2014	2,508,000	2,507,999	99.99	2,508	16,511	2,373
	12/31/2013	2,508,000	2,507,999	99.99	2,508	16,102	5,694
Pro Echo	6/30/2014	131,483,058	91,483,058	69.58	131,483	127,495	632
	12/31/2013	131,483,058	91,483,058	69.58	131,483	126,405	4,165
Lab. Méd. Dr. Sérgio Franco	6/30/2014	63,902,082	63,902,081	99.99	57,536	153,048	40,792
	12/31/2013	63,902,082	63,902,081	99.99	63,902	122,884	69,184
Previlab	6/30/2014	23,113,314	23,009,743	99.56	29,613	33,817	1,792
	12/31/2013	23,113,314	23,009,743	99.56	23,113	25,813	2,778
LAFÊ Serviços Diagnósticos Ltda.	6/30/2014	10,000	9,900	99.00	6,376	6,107	(269)
	12/31/2013	10,000	9,900	99.00	-	-	-
Dasa Property Part.	6/30/2014	50,000	49,500	99.00	50	52	1
	12/31/2013	50,000	49,500	99.00	50	52	2
Dasa Nordeste Part.	6/30/2014	50,000	49,500	99.00	50	51	1
	12/31/2013	50,000	49,500	99.00	50	51	1
Dasa Centro Oeste Part.	6/30/2014	50,000	49,500	99.00	50	51	1
	12/31/2013	50,000	49,500	99.00	50	51	1
Dasa Sudoeste Part.	6/30/2014	50,000	49,500	99.00	50	51	1
	12/31/2013	50,000	49,500	99.00	50	51	1

Notes to Quarterly Information

12.2. Changes in investments

	December 31, 2013	Capital increase	Partial split-off	Proposed and prepaid dividends (c)	Interest on equity	Equity pickup	June 30, 2014
DASA Real Estate	29,733	-	-	-	-	(695)	29,038
CientíficaLab	85,981	-	-	-	-	(2,597)	83,384
CERPE	33,543	-	-	(961)	-	4,614	37,196
CDPI **(a)**	47,368	36,500	-	(2,226)	(3,004)	7,244	85,882
CRMI	16,102	-	-	(1,422)	(542)	2,373	16,511
Pro Echo	88,079	-	-	-	-	632	88,711
Lab. Méd. Dr. Sérgio Franco **(b)**	122,884	-	(6,366)	-	(4,262)	40,792	153,048
Previlab **(a)**	25,813	6,500	-	(288)		1,792	33,817
DASA Finance Investimentos	2,795	-	-	-	-	3,047	5,842
Lafê Serviços Diagnósticos **(b)**	-	10	6,366	-	-	(269)	6,107
Dasa Property Part.	52	-	-	(1)	-	1	52
Dasa Nordeste Part.	51	-	-	(1)	-	1	51
Dasa Centro Oeste Part.	51	-	-	(1)	-	1	51
Dasa Sudoeste Part.	51	-	-	(1)	-	1	51
	452,503	43,010	-	(4,901)	(7,808)	56,937	539,741

(a) Capital payment

CDPI – On February 3, 2014, the Company subscribed and paid 36,500,000 new units of interest of subsidiary CDPI, equivalent to R$ 36,500, based on the 28th amendment to the Articles of Organization of CDPI.

PREVILAB - On February 3, 2014, the Company subscribed and paid 6,500,000 new units of interest of subsidiary PREVILAB, equivalent to R$ 6,500, based on the 16th amendment to the Articles of Organization of PREVILAB.

(b) Partial split-off

In a meeting held on February 28, 2014 of the partners of subsidiary Laboratórios Médicos Dr. Sérgio Franco Ltda. (Sérgio Franco), it was decided to:

i – confirm the appointment and engagement of APSIS Consultoria e Avaliações Ltda. to measure, at carry amount value, split-off equity of subsidiary Sérgio Franco, at December 31, 2013, transferred to Lafê Serviços Diagnósticos Ltda. (Lafê), at February 28, 2014, based on an unqualified approval of the appraisal report, whereby equity of subsidiary Sérgio Franco transferred to Lafê was determined, amounting to R$ 6,366, comprised by cash and cash equivalents amounting to R$ 4,000 and assets related to the business units (establishments) thereof, amounting to R$ 2,366. Equity of subsidiary Sérgio Franco was measured at carry amount value, which took into consideration the accounting records of the balance sheet at December 31, 2013.

Notes to Quarterly Information

ii – approve the "Rationale for Partial Split-off of Laboratórios Médicos Dr. Sérgio Franco Ltda. following the Merger of Net Assets Split Off by Lafê Serviços Diagnósticos Ltda.";

iii – approve, with no reserves, the Partial Split-off of subsidiary Sérgio Franco and merger of net assets split off by Lafê;

iv – approve capital decrease of subsidiary Sérgio Franco amounting to R$ 6,366, corresponding to net assets split off, from R$ 63,902 to R$ 57,536, due to the cancellation of 6,366,316 units of interest of the company. By virtue of such decrease, capital of subsidiary Sérgio Franco now amounts to R$ 57,536.

(c) Proposed and prepaid dividends

Proposed dividends amount to R$ 4,705, corresponding to net income in 2013, and prepaid dividends in the amount of R$ 196, related to the first six-month period of 2014.

13. Property and equipment, net

		Company			
		6/30/2014			12/31/2013
	Average depreciation rate% p.a.	**Cost**	**Accumulated depreciation**	**Net**	**Net**
Properties	**25**	**1,426**	**(876)**	**550**	576
Leasehold improvements	**10**	**397,367**	**(220,521)**	**176,846**	141,761
Machinery and equipment	**12**	**380,266**	**(182,244)**	**198,022**	193,105
Furniture and fixtures	**11**	**57,139**	**(26,191)**	**30,948**	28,526
Facilities	**10**	**32,168**	**(11,597)**	**20,571**	17,371
IT equipment	**20**	**134,708**	**(78,705)**	**56,003**	52,753
Vehicles	**20**	**4,094**	**(3,336)**	**758**	835
Library	**10**	**117**	**(99)**	**18**	21
Land	**-**	**180**	**-**	**180**	180
Acquisitions in progress	**-**	**24,009**	**-**	**24,009**	107,954
		1,031,474	**(523,569)**	**507,905**	543,082

		Consolidated			
		6/30/2014			12/31/2013
	Average depreciation rate % p.a.	**Cost**	**Accumulated depreciation**	**Net**	**Net**
Properties	**4**	**5,166**	**(2,019)**	**3,147**	3,248
Leasehold improvements	**10**	**482,819**	**(248,451)**	**234,368**	196,010
Machinery and equipment	**12**	**498,751**	**(232,857)**	**265,894**	260,153
Furniture and fixtures	**11**	**71,691**	**(31,326)**	**40,365**	37,500
Facilities	**10**	**58,514**	**(19,714)**	**38,800**	36,330
IT equipment	**20**	**151,825**	**(89,385)**	**62,440**	57,979
Vehicles	**20**	**5,524**	**(4,728)**	**796**	978
Library	**10**	**203**	**(134)**	**69**	76
Land	**-**	**6,574**	**-**	**6,574**	6,574
Acquisitions in progress	-	**29,843**	**-**	**29,843**	121,332
		1,310,910	**(628,614)**	**682,296**	720,180

Notes to Quarterly Information

Changes in cost

	Company				
		Changes for the period			
	12/31/13	**Additions**	**Write-offs**	**Transferences(a)**	**6/30/14**
Properties	1,426	**-**	**-**	**-**	**1,426**
Leasehold improvements	344,738	**12,441**	**(189)**	**40,377**	**397,367**
Machinery and equipment	357,011	**15,951**	**(374)**	**7,678**	**380,266**
Furniture and fixtures	51,900	**1,465**	**(43)**	**3,817**	**57,139**
Facilities	27,596	**2,819**	**(85)**	**1,838**	**32,168**
IT equipment	120,717	**4,602**	**(189)**	**9,578**	**134,708**
Vehicles	4,112	**50**	**(68)**	**-**	**4,094**
Library	117	**-**	**-**	**-**	**117**
Land	180	**-**	**-**	**-**	**180**
Construction in progress	107,954	**7,930**	**-**	**(91,875)**	**24,009**
	1,015,751	**45,258**	**(948)**	**(28,587)**	**1,031,474**

	Consolidated				
	Changes for the period				
	12/31/13	**Additions**	**Write-offs**	**Transferences (a)**	**6/30/14**
Properties	5,166	**-**	**-**	**-**	**5,166**
Leasehold improvements	422,952	**15,586**	**(188)**	**44,469**	**482,819**
Machinery and equipment	467,377	**22,960**	**(447)**	**8,861**	**498,751**
Furniture and fixtures	65,332	**1,903**	**88**	**4,368**	**71,691**
Facilities	53,383	**3,128**	**(66)**	**2,069**	**58,514**
IT equipment	135,714	**4,920**	**(169)**	**11,360**	**151,825**
Vehicles	6,156	**51**	**(683)**	**-**	**5,524**
Library	203	**-**	**-**	**-**	**203**
Land	6,574	**-**	**-**	**-**	**6,574**
Acquisitions in progress	121,332	**7,976**	**298**	**(99,763)**	**29,843**
	1,284,189	**56,524**	**(1,167)**	**(28,636)**	**1,310,910**

(a) Expenses made by the Company classified under Construction in progress for the pre-operating period of certain establishments, which are transferred to a specific account of fixed or intangible assets at the beginning of the operating activities.

Notes to Quarterly Information

Changes in accumulated depreciation

	Company				
		Changes for the period			
	12/31/13	Additions	Write-offs	Transferences	6/30/14
Properties	(850)	**(26)**	**-**	**-**	**(876)**
Leasehold improvements	(202,977)	**(17,603)**	**59**	**-**	**(220,521)**
Machinery and equipment	(163,906)	**(17,967)**	**86**	**(457)**	**(182,244)**
Furniture and fixtures	(23,374)	**(2,885)**	**23**	**45**	**(26,191)**
Facilities	(10,225)	**(1,388)**	**16**	**-**	**(11,597)**
IT equipment	(67,964)	**(10,889)**	**181**	**(33)**	**(78,705)**
Vehicles	(3,277)	**(127)**	**68**	**-**	**(3,336)**
Library	(96)	**(3)**	**-**	**-**	**(99)**
	(472,669)	**(50,888)**	**433**	**(445)**	**(523,569)**

	Consolidated				
		Changes for the period			
	12/31/13	Additions	Write-offs	Transferences	6/30/14
Properties	(1,918)	**(101)**	**-**	**-**	**(2,019)**
Leasehold improvements	(226,942)	**(21,568)**	**59**	**-**	**(248,451)**
Machinery and equipment	(207,224)	**(25,293)**	**120**	**(460)**	**(232,857)**
Furniture and fixtures	(27,832)	**(3,565)**	**23**	**48**	**(31,326)**
Facilities	(17,053)	**(2,676)**	**15**	**-**	**(19,714)**
IT equipment	(77,735)	**(11,779)**	**162**	**(33)**	**(89,385)**
Vehicles	(5,178)	**(105)**	**555**	**-**	**(4,728)**
Library	(127)	**(7)**	**-**	**-**	**(134)**
	(564,009)	(65,094)	934	445	(628,614)

(a) Expenses made by the Company classified under Construction in progress for the pre-operating period of certain establishments, which are transferred to a specific account of fixed or intangible assets at the beginning of the operating activities.

Additions to accumulated depreciation, stated in changes for the property and equipment items, were partly recorded under general and administrative expenses and partly under costs of goods and/or services sold.

During the period, the Company did not identify any assets impairment indicator, and also did not capitalize interest.

Notes to Quarterly Information

14. Intangible assets

	Average amortization rate %p.a.	Company 6/30/2014 Cost	Accumulated Amortization	Net	12/31/2013 Cost	Accumulated amortization	Net
Acquisition of interest - Goodwill		**2,116,170**	**(141,766)**	**1,974,404**	2,116,170	(141,766)	1,974,404
Other intangible assets							
IT systems	20	**188,668**	**(112,769)**	**75,899**	151,836	(97,167)	54,669
Commercial area use right	20	**1,433**	**(705)**	**728**	1,203	(592)	611
Other intangible assets	20	**12,628**	**(4,249)**	**8,379**	12,628	(4,249)	8,379
System implementation project	20	**12,293**	**(12,293)**	**-**	12,293	(12,293)	-
Project development	33	**10,259**	**(10,166)**	**93**	10,259	(10,166)	93
Brands	3,3	**236,037**	**(27,757)**	**208,280**	236,037	(23,360)	212,677
Exclusive agreement with customers – Unimagem	10	**9,403**	**(5,023)**	**4,380**	9,403	(4,704)	4,699
Relationship with hospitals	5	**35,748**	**(6,374)**	**29,374**	35,748	(6,001)	29,747
		506,469	**(179,336)**	**327,133**	469,407	(158,532)	310,875
		2,622,639	**(321,102)**	**2,301,537**	2,585,577	(300,298)	2,285,279

	Average amortization rate % p.a.	Consolidated 6/30/2014 Cost	Accumulated Amortization	Net	12/31/2013 Cost	Accumulated amortization	Net
Acquisition of interest – Goodwill		**2,253,591**	**(251,619)**	**2,001,972**	2,253,591	(251,619)	2,001,972
Other intangible assets							
IT systems	20	**194,704**	**(116,853)**	**77,851**	157,519	(100,800)	56,719
Commercial area use right	20	**1,433**	**(706)**	**727**	1,203	(592)	611
Other intangible assets	20	**13,978**	**(4,272)**	**9,706**	13,978	(4,272)	9,706
System implementation project	20	**12,293**	**(12,293)**	**-**	12,293	(12,293)	-
Project development	33	**10,267**	**(10,169)**	**98**	10,267	(10,169)	98
Brands	3.3	**236,037**	**(27,725)**	**208,312**	250,567	(24,970)	225,597
Exclusive agreement with customers - Unimagem	10	**19,270**	**(3,380)**	**15,890**	9,403	(4,707)	4,696
Relationship with hospitals	5	**45,151**	**(11,429)**	**33,722**	40,488	(8,185)	32,303
		533,133	**(186,827)**	**346,306**	495,718	(165,988)	329,730
		2,786,724	**(438,446)**	**2,348,278**	2,749,309	(417,607)	2,331,702

Notes to Quarterly Information

Changes in cost

	Company			
		Changes in the period		
	12/31/13	**Additions**	**Transferences (a)**	**6/30/14**
Acquisition of interest – Goodwill	2,116,170	-	-	**2,116,170**
Other intangible assets				
IT systems	151,836	8,030	28,802	188,668
Commercial area use right	1,203	-	230	1,433
Other intangible assets	12,628	-	-	12,628
System implementation project	12,293	-	-	12,293
Project development	10,259	-	-	10,259
Brands	236,037	-	-	236,037
Exclusive agreement with customers – Unimagem	9,403	-	-	9,403
Relationship with hospitals	35,748	-	-	35,748
	469,407	8,030	29,032	**506,469**
	2,585,577	8,030	29,032	**2,622,639**

	Consolidated				
		Changes in the period			
	12/31/13	**Additions**	**Write-offs**	**Transferences (a)**	**6/30/14**
Acquisition of interest – Goodwill	2,253,591	-	-	-	**2,253,591**
Other intangible assets					
IT systems	157,519	8,380	(46)	28,851	194,704
Commercial area use right	1,203	-	-	230	1,433
Other intangible assets	13,978	-	-	-	13,978
System implementation project	12,293	-	-	-	12,293
Project development	10,267	-	-	-	10,267
Brands	250,567	-	-	(14,530)	236,037
Exclusive agreement with customers – Unimagem	9,403	-	-	9,867	19,270
Relationship with hospitals	40,488	-	-	4,663	45,151
	495,718	8,380	(46)	29,081	**533,133**
	2,749,309	8,380	(46)	29,081	**2,786,724**

(a) Expenses made by the Company classified under Construction in progress for the pre-operating period of certain establishments, which are transferred to a specific account of fixed or intangible assets at the beginning of the operating activities.

Notes to Quarterly Information

Changes in accumulated amortization

	Company			
	Changes in the period			
	12/31/13	Additions	Transf.	6/30/14
Acquisition of interest – Goodwill	(141,766)	-	-	**(141,766)**
Other intangible assets				
IT systems	(97,167)	(15,602)	-	(112,769)
Commercial area use right	(592)	(113)	-	(705)
Other intangible assets	(4,249)	-	-	(4,249)
System implementation project	(12,293)	-	-	(12,293)
Project development	(10,166)	-	-	(10,166)
Brands	(23,360)	(3,749)	(648)	(27,757)
Exclusive agreement with customers - Unimagem	(4,704)	(321)	2	(5,023)
Relationship with hospitals	(6,001)	(1,019)	646	(6,374)
	(158,532)	(20,804)	-	(179,336)
	(300,298)	(20,804)	-	(321,102)

	Consolidated			
	Changes in the period			
	12/31/13	Additions	Reclassifications (b)	6/30/14
Acquisition of interest – Goodwill	(251,619)	-	-	**(251,619)**
Other intangible assets				
IT systems	(100,800)	(16,053)	-	(116,853)
Commercial area use right	(592)	(114)	-	(706)
Other intangible assets	(4,272)	-	-	(4,272)
System implementation project	(12,293)	-	-	(12,293)
Project development	(10,169)	-	-	(10,169)
Brands	(24,970)	(5,275)	2,520	(27,725)
Exclusive agreement with customers - Unimagem	(4,707)	394	933	(3,380)
Relationship with hospitals	(8,185)	209	(3,453)	(11,429)
	(165,988)	(20,839)	-	(186,827)
	(417,607)	(20,839)	-	(438,446)

Additions to accumulated amortization, presented in changes for the period, were recorded under General and administrative expenses, and another portion under Costs of goods sold and/or services rendered.

During the period, the Company did not identify indications of impairment, and also did not capitalize interest.

Notes to Quarterly Information

15. Loans and financing

Type	Average rate	Final maturity	Company		Consolidated	
			6/30/2014	12/31/2013	6/30/2014	12/31/2013
Local currency						
Banco do Brasil **(a) (iii)**	111.0% do CDI	6/1/2015	-	-	18,999	23,884
Banco do Brasil **(iii)**	108.0% do CDI	6/10/2018	-		63,772	
BNDES - FINAME PSI **(v)**	6% p.a	06/15/2024	3,422		3,422	
Financial lease – Sundry banks - Note 26 **(i), (ii)** and **(iii)**	CDI + 2.85% p.a.	10/26/2015	-	2	7,341	11,101
			3,422	2	**93,534**	34,985
Foreign currency						
Financing of equipment **(i)**, **(ii)** and **(iii)**	7.10% p.a.	12/1/2016	-	-	1,929	2,808
Financial lease – Sundry banks - Note 26 **(ii)** and **(iii)**	6.30% p.a.	3/23/2016	3,677	8,429	4,591	10,033
Credit Agricole Bank (**b) (iii) (iv)**	1.32% p.a.	8/20/2014	-	-	66,840	70,623
			3,677	8,429	**73,360**	83,464
Transaction cost – issue of notes (c)			**-**	-	**-**	(1,412)
			7,099	8,431	**166,894**	118,449
Current liabilities			**(3,381)**	(6,628)	**(109,681)**	(100,942)
Noncurrent liabilities			**3,718**	1,803	**57,213**	17,507

Guarantors:

(i) DASA Real Estate Empreendimentos Imobiliários Ltda.

(ii) Promissory Note of 125% of contractual amount in the Company's name.

(iii) Diagnósticos da América S.A.

(iv) Short-term investments with guarantee are securities of public and private entities acquired by subsidiary DASA Finance Corporation.

(v) Financed asset.

Loan and financing agreements do not have covenants.

(a) This refers to fundraising for working capital in subsidiaries Sérgio Franco, CDPI and CRMI.

Notes to Quarterly Information

(b) This refers to loan transactions with subsidiary DASA Finance Corporation, in order to exercise the call option for all notes issued by DASA Finance, maturing in 2018 (8.75% Senior Notes due 2018).

(c) The transaction cost amounts were appropriated to income on the repurchase date of Notes.

Loans and financing classified as non-current liabilities, according to the contractual maturity dates, will be repaid as follows:

	Company	Consolidated
As from 07/2015	244	9,745
2016	283	18,561
2017	426	17,568
2018	426	9,000
2019 a 2024	2,339	2,339
	3,718	57,213

Notes to Quarterly Information

The Company granted collaterals to its subsidiaries as follows:

CDPI - Clínica de Diagnóstico por Imagem Ltda	Banco ABC Brasil	4,521
	General Eletric	2,542
	Banco Itaú S.A.	1,985
	Banco do Brasil	65,000
	Santander	2,043
CientificaLab Produtos Lab. e Sistemas Ltda.	Banco Pottencial	409
DASA Finance Corporation	Banco do Brasil	51,759
Laboratórios Médicos Dr. Sérgio Franco Ltda.	Banco do Brasil	25,000
	Banco Itaú S.A.	1,227
	Banco Potencial	10
Pro Echo Cardiodata Serviços Médicos Ltda.	General Eletric	8,076
	Banco Itaú S.A.	1,099
CRMI - Clínica de Ressonância e Multi Imagem Ltda.	Banco do Brasil	4,000
	Banco Itaú S.A.	2,014
		169,685

Notes to Quarterly Information

16. Debentures (Company and consolidated)

	6/30/2014	12/31/2013
Nonconvertible debentures	1,104,167	1,337,500
Compensatory interest	23,607	26,160
	1,127,774	1,363,660
Transaction cost	(5,893)	(6,934)
	1,121,881	1,356,726
Current	(317,359)	(319,912)
Noncurrent	804,522	1,036,814

Deadline for amortization of the main value of second- and third-issue debentures is as follows:

10/25/2014	62,500
04/29/2015	233,333
10/25/2015	62,500
04/29/2016	233,334
10/25/2016	62,500
10/17/2017	225,000
10/17/2018	225,000
	1,104,167

2nd Issue

In the meeting held on March 16, 2011, the Board of Directors of the Company approved a fund raising by conducting the 2nd issue of simple debentures non-convertible into shares of the Company, for public distribution in the total amount of up to R$810,000, on a firm guarantee and better efforts of placement basis, under the terms of CVM Ruling No. 476 of January 16, 2009, as amended.

Notes to Quarterly Information

On May 16, 2011, the Company communicated to its shareholders and the market in general that on May 11, 2011, it closed the public offer for distribution with restricted placement efforts, of a single series of simple debentures non-convertible into shares, of the unsecured type. Seventy thousand 70,000 debentures were subscribed for a 5-year term from the date of issue, in the total amount of R$ 700,000. The debenture remuneration is equivalent to 100% of the accumulated variation of the Inter-financial Deposit (DI) daily average rates, “over extra-group”, expressed in percentage per annum and based on 252 working days, as calculated and daily disclosed by the Clearing House for the Custody and Financial Settlement of Securities (CETIP), plus an exponential surcharge of 1.40%. As the issue date was April 29, 2011, the face value of each debenture will be paid in 3 consecutive annual installments, as from the 36th month from the issue date. Payment of remuneration interest is semiannual, occurring on the 1st day of April and October, and the debit in the Company account shall occur one day prior to due date.

<u>3rd Issue</u>

On October 15, 2012, the Board of Directors of the Company approved the third issue by the Company, of up to 25,000 debentures non-convertible into shares of the unsecured type, in a single series, in the total amount of up to R$250,000, for placement through a public offer with restricted efforts, pursuant to CVM Instruction No. 476 of January 16, 2009, as amended.

On November 1, 2012, the Company communicated to its shareholders and the market in general that on October 31, 2012 it had closed the public offer for distribution, with restricted placement efforts, of the third issue of DASA’s simple debentures non-convertible into shares, of the unsecured type, in one single series. Twenty-five thousand (25,000) debentures were subscribed for a 4-year term from the date of issue, in the total amount of R$ 250,000. The debentures are not subject to monetary adjustment, and the debit balance of each debenture face value will incur an interest equivalent to 100% of the accumulated variation of the Inter-financial Deposit (DI) daily average rates, “over extra-group”, expressed in percentage per annum and based on 252 working days, as calculated and daily disclosed by CETIP, plus a surcharge of 0.80% per annum, calculated based on 252 business days, exponentially and cumulatively, on a pro rata temporis basis, per business day elapsed from the Date of Issue or the payment date of the immediately prior remuneration, as the case may be, until the effective payment date.

Interest will be paid semiannually from the Issue Date, the first payment beginning on April 25, 2013 and the last payment to be made on the Maturity Date, without prejudice to payments resulting from early redemption of the Debentures, early repayment of the Debentures and/or prepayment of obligations arising out of the Debentures.

Notes to Quarterly Information

The face value of each Debenture will be repaid in 4 annual and successive installments, in the following order:

I. Three installments, each in the amount corresponding to 25% of the face value of each Debenture, due on October 25, 2013, October 25, 2014 and October 25, 2015; and

II. One installment in the amount corresponding to the outstanding balance of the face value of each Debenture, due on October 25, 2016.

The financial settlement of the offer occurred on October 31, 2012 in the amount of R$250,304, and the net proceeds of the offer were used towards (i) the early redemption of all commercial promissory notes of the third issue of the Company; and (ii) the balance to reinforce the working capital of the Company.

4th Issue

On September 13, 2013, the Company's Board of Directors approved the fourth issue of debentures by the Company, in a single series of up to 45,000 unregistered debentures not convertible into shares totaling up to R$ 450,000 for placement through public offering with restrict placement efforts under the terms of CVM Rule No. 476 of January 16, 2009, as amended.

On October 18, 2013, the Company communicated its shareholders and the general market that the public offering with restrict placement efforts of simple, unregistered debentures not convertible into shares, in a single series, of the 4^{th} issue was concluded on October 17, 2013. 45,000 debentures, effective for 5 years from issue date, amounting to R$ 450,000 were subscribed. These debentures will not be subject to monetary restatement and, over the debt balance of the nominal value of each debenture, compensatory interest will be levied, corresponding to 100% of accumulated daily average interbank deposits (DI) rate, "over extra-group", expressed in percentage per year, on a 252 business days basis and disclosed by CETIP plus a surtax of 1.15% per year, on a 252 business days basis, computed on an exponential and cumulative manner, pro rata temporis, per business days elapsed since payment day or the date when the prior remuneration is paid, as the case may be, until the effective payment.

Remuneration is to be paid on a half-yearly basis as from issue date, with first payment on April 15, 2014, and last payment on maturity date, not affecting payments made referring to anticipate redemption of debentures, early amortization of debentures and/or early maturity of obligations arising from debentures.

Principal amount will be amortized in two annual installments, in the 48th and 60th month, as from the debentures issue date.

Financial settlement of this offering occurred on October 16, 2013, amounting to R$450,000, and the net funds from the offering were used to reinforce the working capital and refinancing of debts.

Notes to Quarterly Information

The debentures have clauses determining the maximum indebtedness and leverage levels, based on the consolidated quarterly financial information.

At the end of the first semester of 2014, the Company was in compliance with the contractual conditions, as follows:

Indicator	Contractual terms (a)	Condition at 6/30/14	Condition at 12/31/13
EBITDA – Last 12 months (b)		461,263	443,594
Financial income – Last 12 months (b)		101,932	86,584
Net debt		791,466	866,209
1- Net debt / *EBITDA* – maximum index			
2ª Issuance	2.50	1.72	1.95
3ª Issuance	3.00	1.72	1.95
4ª Issuance	3.00	1.72	1.95
2- *EBITDA* / Financial income – minimum index			
2ª Issuance	2.00	4.53	5.12
3ª Issuance	2.00	4.53	5.12
4ª Issuance	2.00	4.53	5.12

(a) The Company will be deemed to be in non-compliance with this covenant if it exceeds such ratios for two consecutive quarters
(b) The information and EBITDA are not part of the scope of the auditor's review work.

Notes to Quarterly Information

17. Taxes in installments

		Company		Consolidated	
	Completion of payments	**6/30/2014**	**12/31/2013**	**6/30/2014**	**12/31/2013**
REFIS IV – Federal **(a)**	2020	9,522	9,678	17,794	18,853
ICMS – RJ **(a) e (b)**		-	-	1,857	5,102
ISS – CERPE		-	-	2,751	2,848
ISS – CRMI		-	-	440	-
Other		757	860	1,620	2,382
		10,279	10,538	**24,462**	29,185
Current		**(867)**	(1,108)	**(2,636)**	(4,293)
Noncurrent		**9,412**	9,430	**21,826**	24,892

(a) The variations occurred in the first half of 2014 are related to interest and payments during the period updates.

The details of these tax installments are presented in note 19 of the financial statements for the year ended December 31,2013.

(b) Installment ICMS – R

On February 25, 2014, an order from the State Department for Civil Affairs was published in the Rio de Janeiro State Official Gazette (DOERJ) which formalized the deferral of administrative proceeding E14-515.135/2012 corresponding to one (1) of two (2) requested offset of VAT credit taxes presented by CRMI. Accordingly, the VAT tax credits has already been recorded through both the write-off of State VAT (ICMS) tax debits stated in that request, as well as the respective court ordered debt used which totaled R$ 2,945. Furthermore, the portion of negative goodwill relating to that court ordered debt was also recognized under Financial expenses at the amount of R$ 960. Payment of 5% of the tax amnesty amount, not offsettable by the court ordered debt was made on June 3, 2014, on notice from the PGE (State Attorney General)

Notes to Quarterly Information

18. Accounts payable for acquisitions of subsidiaries

Accounts payable for acquisition of subsidiaries relate to the amounts due to their former owners upon the acquisition of shares or quotas representing the paid-in capital of these companies. Debts are restated in accordance with contractual clauses:

			Company		Consolidated	
	Restatement	Maturity	6/30/2014	12/31/2013	6/30/2014	12/31/2013
Not guaranteed by marketable securities	IPCA-IGPM-Selic	05/2016	8,291	10,566	8,291	10,566
Guaranteed by marketable securities	(a)	11/2016 and 04/2017	24,262	26,184	36,384	37,793
			32,553	36,750	44,675	48,359
Current			(1,735)	(1,689)	(1,735)	(1,689)
Noncurrent			30,818	35,061	42,940	46,670

(a) Restated at the average rate of 101.33% of CDI (101.25% of CDI at December 31, 2013) for fixed-income funds, and 102.36% of CDI (100.01% of CDI at December 31, 2013) for CDB/ committed transactions, which are managed by financial entities, as shown in Note 8.

The installments classified as non-current liabilities have the following payment schedule:

Aging list	Company	Consolidated
As from 07/2015	13,435	13,435
2016	17,267	24,986
2017 a 2020	116	4,519
Total	30,818	42,940

Notes to Quarterly Information

19. Provisions for tax, social security, labor and civil proceedings

	Company			
	6/30/2014		12/31/2013	
	Provision	Judicial deposit	Provision	Judicial deposit
ICMS on import **(a)**	4,947	965	4,942	54,696
Labor and civil contingencies **(b)**	15,776	10,056	6,496	9,677
Tax contingencies **(c)**	26,422	25,611	26,056	26,322
	47,145	**36,632**	37,494	90,695

	Consolidated			
	6/30/2014		12/31/2013	
	Provision	Judicial deposit	Provision	Judicial deposit
ICMS on import **(a)**	4,947	965	4,942	54,696
Labor and civil contingencies **(b)**	16,279	13,550	6,997	13,121
Tax contingencies **(c)**	28,872	27,014	28,506	27,723
	50,098	**41,529**	40,445	95,540

(a) ICMS on import

Following the opinion of its legal advisors, the Company has not paid ICMS on the import of inputs and equipment for use in the rendering of its services since February 2000, as there are ongoing discussions as to whether the Company is an ICMS taxpayer for these transactions. For ICMS payables on goods and equipment imported up to the publication of Constitutional amendment 33 on December 11, 2001, the external legal advisors understand that the likelihood of losses is remote; as regarding to ICMS payables generated between the Constitutional Amendment 33 date and the issuance of the supplementary Law No. 114, on December 16, 2002, the likelihood of loss was classified as possible. For import of equipment under the lease modality, the likelihood of loss was also deemed as possible. Finally, after enactment of the supplementary Law No. 114 on December 16, 2002, the external legal advisors understand that the likelihood of loss is probable.

Of the amount of R$ 54,696, which represented the restated balance of December 31, 2013 of the judicial deposits amount, R$ 53,732 corresponded to the restated amount of deposit in December 2011 (to the original deposit amount R$46,849) referring to ICMS amounts charged on direct import transactions of inputs and equipment cleared in the state of São Paulo, for which no process was served, pledging the voluntary payment of taxes, without fines and with decreased interest, maintaining the criteria for computation of provision amounts. Because the Company had adhered to PEP of ICMS/SP in 2013, which covered all tax debts guaranteed by this deposit, the determination of the judicial deposit amount was required. On February 25, 2014, the Company, completed the calculation of ICMS on direct imports, deposited in court in December 2011, based on MS records No. 0046827-27.2011.8.26.0053.

Notes to Quarterly Information

(b) Provision for labor and civil contingencies

At June 30, 2014, the Company is a party to 1,479 labor claims (1,306 at December 31, 2013) and 1,172 administrative and legal civil claims (1,122 at December 31, 2013). The provisions of R$ 15,776 (R$ 6,496 at December 31, 2013) in Company and R$ 16,279 (R$ 6,997 at December 31, 2013) in Consolidated are based on the historical percentage of probable and possible unfavorable outcomes. Additionally, at June 30, 2014, there were R$ 113,579 (R$ 109,260 at December 31, 2013) in Consolidated related to proceedings whose unfavorable outcome is possible, based on the opinion of legal advisors, R$ 18,879 referring to civil claims and R$ 94,760 to labor claims, for which no provision was set up, in accordance with the accounting standard applicable thereto.

The Company is also a party to a lawsuit for indemnification for loss of profits and pain and suffering due to supposed competition-related infraction by the Company together with a health insurance Company. An opposition was filed against the case amount against which claimants filed a reply, as such, an expert accounting and engineering examination was ordered. On December 7, 2007, the amount attributed to the case by claimant is R$ 61,815, which unfavorable outcome was classified as possible, and the amount involved has not been evaluated. An expert accounting examination conducted by the court expert concluded that the claimed loss of profit sought should amount to R$ 4,500, applicable to the healthcare company and not to the Company.

From the amount of R$ 94,760 corresponding to labor claims classified as possible loss, we should mention the Public Civil Action at the Rio de Janeiro Labor Court, to which the Company and its subsidiary Laboratórios Médicos Dr. Sérgio Franco Ltda. are a party. In general, questioning the legality of the arrangements with health companies specialized in diagnostic support services by imaging, which required hiring doctors bound to said healthcare companies under the Consolidation of Labor Laws (CLT) and a collective indemnification for pain and suffering of approximately R$ 20,000 on September 10, 2012. On June 26, 2014, the Company released a new Material Fact disclosing that a decision was handed down entirely favorable to the Company in the lower court. The decision can still be appealed by the Ministry of Labor. The Company believes that, considering their specific characteristics, the arrangement principles which is being adopted, in addition to being in regular and in strict compliance with applicable laws, are supported by favorable former court decisions, and are in line with the disclosures and explanations reported in the Reference Form, in items 4.1 and 4.3.

Notes to Quarterly Information

(c) Provision for tax contingencies

The provisions for tax contingencies in the amount of R$ 26,422 (R$ 26,056 at December 31, 2013) in Company, and R$ 28,872 (R$ 28,506 at December 31, 2013) in consolidated, relate to: (i) questionings for increases in rates; (ii) calculation base; and (iii) unconstitutionality of collection. Such questionings refer basically to PIS, COFINS, INSS and FGTS contributions. At June 30, 2014, the Company recorded a consolidated amount of R$ 274,765 (R$ 265,768 at December 31, 2013), related to claims classified by its legal advisors as possible loss, for which there were no provisions, according to the accounting rule applicable for those circumstances, and substantially R$ 172,550 was related to ICMS claims (Taxes) over import of leasing equipment and direct import of inputs and equipment performed between the EC33 (issued in December 2001) and the Supplementary Law No. 114 (issued in December 2002), and R$ 102,215 related to other PIS, COFINS, IRPJ and ISS tax claims.

Changes in provisions for contingencies

	Company				
	12/31/2013	**Change for the period**			**6/30/2014**
	Closing balance	**Additions to provision**	**Use and reversal**	**Restatement**	**Closing balance**
ICMS on import	4,942	-	(171)	176	4,947
Provision for labor and civil contingencies	6,496	13,104	(3,824)	-	15,776
Provision for tax contingencies	26,056	-	(6)	372	26,422
	37,494	**13,104**	**(4,001)**	**548**	**47,145**

	Consolidated				
	12/31/2013	**Change for the period**			**6/30/2014**
	Closing balance	**Additions to provision**	**Use and reversal**	**Restatement**	**Closing balance**
ICMS on import	4,942	-	(171)	176	4,947
Provision for labor and civil contingencies	6,997	13,106	(3,824)	-	16,279
Provision for tax contingencies	28,506	-	(6)	372	28,872
	40,445	**13,106**	**(4,001)**	**548**	**50,098**

(a) Additional provision for labor and civil contingencies refers to new proceedings filed against the Company for the six-month period according to the history of losses.

Notes to Quarterly Information

20. Equity

a) Share-based payment

Changes in the period of options granted in May 2011:

	Common shares	R$
Balance at December 31, 2013	92,754	1,350
Additions	13,822	301
Equity-settled transactions **(a)**	106,576	(1,651)
Balance at June 30, 2014	**-**	**-**

(a) The Board of Directors approved at a meeting held on May 27, 2014, the transfer of 106,576 treasury shares in private transactions to beneficiaries and holders of stock option related to the First Program plan. These treasury shares were granted and exercised in accordance with their terms and conditions, in compliance with the provisions of section 5 of the First Program, and as permitted by Article 3, section II of CVM Ruling No. 390, dated July 8, 2003. Considering the amount of R$15.49 per share at the close of business on BM&FBovespa on May 27, 2014, the amount of R$1,651 was recorded as a settlement of the options granted in May 2011.

Share-based payment transactions - June 2012

	Common shares	R$
Balance at December 31, 2013	107,592	1,567
Additions	35,152	436
Balance at June 30, 2014	**142,744**	**2,003**

Details of the Stock Option Plan are shown in Note 22 (e) of the financial statements for year ended December 31, 2013.

Notes to Quarterly Information

b) Treasury shares

Description of operation	Number of shares	Amount	Average price per share
Balance at December 31, 2013	1,159.035	18,617	16.06
Transfer (a)	(106,576)	(1,712)	16.06
Balance at June 30, 2014	1,052,459	16,905	16.06

(a) Transfer refers to the settlement of options granted in the amount of R$ 1,651, as disclosed in item (a) of this note, plus R$ 61 adjustment related to the average historical value per share of treasury shares, registered against Special Goodwill Reserve on Merger account.

c) Earnings per share

Basic

Basic earnings per share are calculated by dividing the income attributable to the Company's shareholders by the weighted average number of common shares issued over the period, less common shares purchased by the Company and held as treasury shares.

	1/1/2014 a 6/30/2014	1/1/2013 a 6/30/2013
Income attributable to Company shareholders	60,330	58,681
Weighted average number of common shares issued	311,803	311,803
Weighted average of treasury shares	(1,052)	(1,159)
Weighted average of outstanding common shares	310,751	310,644
Basic earnings per share - R$	0.19414	0.18890

Diluted

Diluted earnings per share are calculated by adjusting the weighted average number of outstanding common shares considering the conversion of all potential common shares that would cause dilution. The Company has only one category of dilutive potential common shares: stock options, disclosed in item (a) of this Note.

	1/1/2014 a 6/30/2014	1/1/2013 a 6/30/2013
Income attributable to Company shareholders	60,330	58.681
Weighted average of outstanding common shares	310,751	310,644
Adjustment for acquisition of shares	212	335
Weighted average number of common shares for diluted earnings per share	310,963	310,979
Diluted earnings per share - R$	0.19401	0.18870

Notes to Quarterly Information

21. Income and social contribution taxes

The company records monthly provisions for income and social contribution taxes on an accrual basis.

Taxes are calculated by taxable income, except for subsidiaries Imagem e Diagnóstico, Multimagem PET, Multi-Imagem Petrópolis Dasa Centro Oeste, Dasa Nordeste, Dasa Sudoeste and Dasa Property, in which it adopted the presumed profit system.

Reconciliation of the expense calculated by applying combined rates for income and social contribution tax expenses charged to income is shown as follows:

	Company		Consolidated	
	6/30/14	6/30/13	6/30/14	6/30/13
Income before income and social contribution taxes	67,097	75,254	88,625	91,250
	34%	34%	34%	34%
Income and social contribution taxes: at combined tax rate	(22,813)	(25,586)	(30,133)	(31,025)
Permanent exclusions (additions)				
Equity pickup	19,359	9,677	-	-
Interest in paid-in capital	(2,655)	-	-	-
Nondeductible expenses	(658)	(510)	(676)	(538)
Other adjustments				
Income of subsidiary abroad	-	-	1,036	(2,499)
Taxable profit computed as a percentage of gross sales (Deemed profit taxation)	-	-	509	500
Goodwill on downstream merger	-	-	764	764
Other	-	(154)	408	280
	(6,767)	(16,573)	(28,092)	(32,518)
Current income and social contribution Taxes	-	-	(21,348)	(20,034)
Deferred taxes	(6,767)	(16,573)	(6,744)	(12,484)
Total	(6,767)	(16,573)	(28,092)	(32,518)
Effective rate	10%	22%	32%	36%

The 34% combined tax rate used for 2014 and 2013 calculations applies to taxable profit for legal entities in Brazil as required by the tax laws of this jurisdiction.

Notes to Quarterly Information

Deferred taxes on tax losses and temporary provisions

Income and social contribution taxes are stated so as to reflect future tax effects attributable to temporary differences between the assets and liabilities tax bases and their respective book values.

In accordance with CPC 32, based on the expectation of generating future taxable profit backed by a technical study approved by our management, the Company recognizes tax credits and debits on deductible temporary differences and accumulated tax losses and negative bases for social contribution, which are not subject to limitation and may be used to offset up to 30% of annual taxable profit. The book value for deferred tax assets and liabilities is reviewed quarterly and projections are reviewed annually.

The composition of the balances of deferred income and social contribution taxes assets and liabilities are shown below

	Balance sheet Company		Income (loss) Company
	6/30/14	**12/31/13**	**6/30/14**
Income tax losses and negative basis for social contribution	197,558	169,286	28,272
Allowance for doubtful accounts and disallowances	15,055	15,748	(693)
Provision for specialized medical services	10,701	9,820	881
Sundry provisions	7,391	5,701	1,690
Provision for contingencies	11,959	7,767	4,192
Other	1,157	623	535
Goodwill amortization	(237,771)	(194,206)	(43,565)
Intangibles identified in acquisitions	(82,417)	(84,218)	1,801
Review of property and equipment useful lives	(11,826)	(11,870)	44
Outros	(785)	(861)	76
Deferred income and social contribution taxes - Assets / (Liabilities)	**(88,978)**	**(82,211)**	**-**
Revenue (expenses) from income and social contribution – deferred	**-**	-	**(6,767)**
Reflected in the balance sheet as follows:			
Deferred tax assets	-	-	
Deferred tax liabilities	(88,978)	(82,211)	
Deferred income and social contribution taxes - Assets /(Liabilities)	**(88,978)**	**(82,211)**	

Reconciliation of tax assets (liabilities) - deferred	**6/30/14**
Balance at December 31, 2013	**(82,211)**
Income / (expenses) from taxes recognized in income (loss)	**(6,767)**
Balance at June 30, 2014	**(88,978)**

Notes to Quarterly Information

	Balance sheet Consolidated		Income (loss) Consolidated
	6/30/14	12/31/13	6/30/14
Income tax losses and negative basis for social contribution	239,871	208,656	31,215
Allowance for doubtful accounts and disallowances	23,096	22,874	222
Goodwill amortization	14,706	18,850	(4,144)
Provision for specialized medical services	13,672	12,252	1,420
Sundry provisions	7,406	5,701	1,705
Provision (-)Obsolete items	139	-	139
AVP – Accounts receivable long term	371	-	371
Provision for contingencies	12,827	8,634	4,193
Other	1,157	773	384
Goodwill amortization	(239,123)	(195,385)	(43,738)
Intangibles identified in acquisitions	(87,816)	(89,728)	1,912
Review of useful life of property and equipment	(9,228)	(9,144)	(84)
Other	(8,031)	(7,692)	(339)
Deferred income and social contribution taxes - Assets/ (Liabilities)	**(30,953)**	**(24,209)**	
Revenue (expenses) from income and social contribution taxes - deferred			**(6,744)**
Reflected in the balance sheet as follows:			
Deferred tax assets	58,812	58,002	
Deferred tax liabilities	(89,765)	(82,211)	
Deferred income and social contribution taxes - Assets/ (Liabilities)	**(30,953)**	**(24,209)**	

Reconciliation of deferred tax assets (liabilities)	**6/30/14**
Balance at December 31, 2013	(24,209)
Income / (expenses) from taxes recognized in income (loss)	(6,744)
Other	
Balance at June 30, 2014	**(30,953)**

Company management considers that the deferred income and social contribution tax asset balances from temporary expenses will be realized to the proportion of the contingencies and realization of events triggering such provisions for losses.

The Company did not identify evidence that deferred taxes will not be recoverable over the semester.

Notes to Quarterly Information

22. Cost of services provided

	Company		Consolidated	
	6/30/2014	6/30/2013	6/30/2014	6/30/2013
Personnel	187,821	163,430	262,785	229,835
Material	162,742	137,203	243,667	211,408
Services and utilities	271,446	254,192	346,478	330,865
Depreciation and amortization	40,963	40,558	54,335	52,103
General expenses	12,933	8,587	16,709	12,552
	675,905	603,970	923,974	836,763

23. General and Administrative Expenses by nature

	Company		Consolidated	
	6/30/2014	6/30/2013	6/30/2014	6/30/2013
Personnel expenses	85,557	82,808	117,875	110,106
Provision for profit sharing and bonus	19,800	13,922	19,800	13,922
Services and utilities	41,059	30,320	59,894	47,975
Advertising and publicity	4,170	4,454	4,799	5,126
Freight costs	17,813	16,741	21,132	18,930
Depreciation and amortization	30,728	25,460	31,559	27,432
Taxes and charges	622	3,005	1,380	4,622
Sundry provisions (a)	14,137	3,791	14,878	4,739
General expenses	10,281	8,726	13,656	14,952
	224,167	189,227	284,973	247,804

(a) Additional provision for labor and civil contingencies as disclosed in Note 19.

24. Financial instruments

The Company is generally exposed to the following operating risks that may affect its strategic and financial objectives to a greater or lesser extent:

- Market risk
- Liquidity risk
- Credit risk
- Operating risk

Notes to Quarterly Information

The Company manages the risks to which it is exposed by defining conservative strategies to ensure liquidity, profitability, and security, using objective criteria for risk diversification.

This note reports the Company's exposure to each of the above risks, and its objectives, policies and processes for risk measurement and management and for capital management.

Risk management structure

In alignment with current regulations and with the Company's corporate policies, the system is based on the integrated management of each of the business processes and on adjusting risk level to strategic objectives. The Company's corporate governance structure involves an extensive risk management process for identifying, treating, and monitoring these risks that extends from senior management, and institutional committees such as the auditing committee, which is responsible, among other duties, for overseeing the integrity and effectiveness of internal controls and risk management through to all the Company's different areas.

The Company's internal control environment has been designed to support the nature, risk, and complexity of its operations. It is based on formalized policies and procedures that are disseminated throughout the organization, as well as dedicated business areas and specific tools for risk monitoring.

Management of all risks inherent to the Company's activities on an integrated basis is addressed within a process supported by the structures of Internal Controls and Compliance (in relation to internal policies, rules, and regulations) that ensures continuous improvement for risk management models and minimizes any omission that could jeopardize correct risk identification and assessment. Based on identification, assessment and monitoring of the principal risks, the Company draws up specific action plans to ensure that improvements are implemented.

To build the right control environment for the scale of its business, the Company invests to strengthen internal communication and disseminate the risk management concept among employees. Corporate risk management is supported by statistical tools with liability adequacy testing, stress testing, capital sufficiency indicators and others. In addition to these tools, the Company adds the qualitative side of risk management, with results from self-assessment, quality evaluations, and tests conducted by internal auditing to evaluate the effectiveness and efficiency of internal controls, as well as quality performance in fulfilling duties and responsibilities.

Historically, the financial instruments used by the Company have shown adequate results for risk mitigation. Additionally, we avoid transactions involving exotic or speculative derivatives.

Market risks

These are risks related to assets and liabilities with cash flows or present values that are exposed to:

Notes to Quarterly Information

a) *Exchange-rate risk*: Risk of loss or gain depending on fluctuations in prices of foreign currencies. The main tool to control exchange-rate related risk is the daily treasury position, which is based on reports provided by the BM&FBovespa and other sources (e.g. the Central Bank) for the control of exchange-rate variations involved in our operations.

b) *Market risk - interest*: Risk of fluctuating interest rates leading to increased expenses or decreased income. Fixed interest rates maintained to maturity allow certainty for cash flows. Floating interest rates pose volatility for future interest charges. The main tool for control of risk related to interest rates is the daily treasury position, which is based on reports provided by the BM&FBovespa to control interest rates involved in our transactions.

   Our principal market risks arise from possible fluctuations in interest rates and exchange rates. As a result, the Company and its subsidiaries seek hedging for liquidity risk through financial instruments such as marketable securities, funding in the form of working capital loans, and funding through the issue of debentures, all on an arms' length basis, as well as USD-CDI index swaps.

   The Company's market risk management practices are based on the operating strategies and internal controls established in its Internal Policy for Risk Management of Financial Assets ("Policy") in order to ensure liquidity, profitability, and security of financial instruments exposed to risk. These practices consist of periodically monitoring its contractual conditions in comparison with current market conditions.

   Every financial transaction is submitted to the Executive Committee and subsequent validation by the board of directors and / or their auxiliary advisory committees. In the cases of exchange rate and interest-rate exposure, guidelines are set by the board of directors and operated by the Treasury department, since they depend of variable components of the economic scenario. Treasury forwards a monthly report to the Executive Committee showing the Company's current exposure to market risks and using reports, documents and contracts checks for compliance with the policy.

In addition to the above, for market risks to which the Company is exposed, Treasury is mandated to run monthly stress tests assuming 25% and 50% variations in relation to original parameters in order to assess the elasticity of these positions when subjected to major variations of the rates involved in these transactions, and their impact on income and cash positions of the Company.

Liquidity risk

Liquidity risk is the risk of an unforeseeable event or an error in calculating liquidity requirements that will impact the Company's investment decisions or day-to-day business.

We manage liquidity risk by maintaining adequate reserves, bank credit facilities, and credit lines from funding as deemed appropriate, continuously monitoring expected and actual cash flows and the combination of maturity profiles of financial assets and liabilities, following these guidelines:

Notes to Quarterly Information

a) Short-term cash management - liquid assets and credit facilities to cover immediate needs. Periodicity: Daily. Periodicity: D+1 (working days);

b) Long-term cash management - Continuous process to ensure long-term funds, through analysis of the cash budget on a monthly basis, updating assumptions made in the budget in accordance with business needs, and comparing actual *versus* estimated performance. Periodicity: Monthly. Term: 5th working day of the month following the report's base date;

c) Maintenance of minimum cash - Refers to cash balances the Company may replenish in a very short period of time to meet any urgent requirements. In addition, it uses the criterion that cash holdings must be sufficient to cover the five worst daily cash flows in a month, not including receivables;

d) Exposure limits and risk mitigation - the treasury department keeps short-term facilities for immediate liquidity and working capital lines, so that volume is sufficient to ensure at least the amount equal to that of the highest cash outflow over five consecutive days in the last 12 months.

For medium and long term credit lines, the Treasury department maintains credit lines compatible with the Company's strategic planning, for the purpose of ensuring the availability of resources to meet the estimated cash flow.

The table below details the aging list of the consolidated financial liabilities at June 30, 2014:

Consolidated	**Maturity**				
Transaction	**2014**	**2015**	**2016 a 2017**	**2018 onwards**	**Total**
Derivative liabilities	310	26	-	-	336
Trade accounts payable	81,180	-	-	-	81,180
Loans and financing	109,681	9,745	36,130	11,338	166,894
Debentures	317,359	61,480	518,689	224,353	1,121,881
Taxes in installments	2,636	2,578	3,361	15,887	24,462
Payables for acquisition of subsidiaries	1,735	13,435	29,505	-	44,675
	512,901	87,264	587,685	251,578	1,439,428

Credit risk

Refers to the risk of loss resulting from inability of the counterparty to meet its contractual obligations and make payments to the Company. The principal means of mitigating this risk is through the credit analysis process. Measurement of credit risk over time will be based mainly on the determination of the allowance for doubtful accounts.

Notes to Quarterly Information

The Company and its subsidiaries are subordinated to the credit policy set by its management and their purpose is to minimize any problems deriving from default due to disallowances under plans. The Company also set up an allowance for doubtful accounts due to disallowances, default and returned checks in the Company amounting to R$ 44,278 (R$ 46,318 at December 31, 2013) representing 9.73% (10.62% at December 31, 2013) from the balance of outstanding receivables in order to cover credit risk, and in Consolidated R$ 68,170 (R$ 67,486 at December 31, 2013) representing 9.55% (10.56% at December 31, 2013) from the balance outstanding receivables in order to cover the credit risk.

At June 30, 2014, the maximum exposure in consolidated was R$ 1,155,570 (R$ 1,175,059 at December 31, 2013) referring to cash and cash equivalents and receivables.

Operating risk

Operating risk is the risk of direct or indirect loss arising from a variety of causes associated with our personnel, technology and infrastructure processes, as well as external factors, other than credit, market and liquidity risks. It includes risks such as those arising from legal and regulatory requirements and generally accepted standards of corporate conduct. Operating risks arise from all our operations.

The objective of the Company is to manage operating risk to prevent the occurrence of financial losses or damage to its reputation while ensuring cost effectiveness and avoiding control procedures that hamper initiative and creativity.

The primary responsibility for developing and implementing controls to cover operating risk is attributed to senior management. The latter is supported by development of overall standards for operating risk management in the following areas:

- requirements for appropriate segregation of duties, including independent authorization of transactions;
- requirements for reconciliation and monitoring transactions;
- compliance with legal and regulatory requirements
- documentation of controls and procedures;
- requirements for periodic assessment of operating risks faced, and adequacy of controls and procedures to treat the identified risks;
- requirements for reporting transaction losses and proposed corrective measures;
- developing contingency plans;
- professional training and development;
- ethical and business standards;
- risk mitigation, including insurance, when effective

Notes to Quarterly Information

Compliance with the Company's rules is supported by a continuous quality assessment process and a program for periodical analysis of the Internal Auditing responsibilities. The results of the Internal Auditing analyses are discussed with the management of the related business unit, and reports are sent to the Auditing Committee and to the Company management.

Capital management

The Company monitors the financial leverage to maintain an appropriate capital structure for the operation and to reduce the indebtedness cost. The leverage ratio used corresponds to net debt divided by total equity.

The consolidated levels of financial leverage ratios at June 30, 2014 and December 31, 2013 are broken down as follows:

	6/30/2014	**12/31/2013**
Loans and financing **(a)**	166,894	118,449
Debentures **(a)**	1,121,881	1,356,726
Derivative financial instruments	336	(107)
Total gross debt	1,289,111	1,475,068
Cash and cash equivalents and marketable securities – current assets	(497,643)	(608,861)
Net debt	791,468	866,207
Equity	2,769,885	2,708,810
Contents	0.28574	0.31977

(a) Amounts are reported net of transaction costs

The Company may alter its capital structure depending on economic-financial, strategic or operational conditions, in order to improve debt management. At the same time, it aims to improve return on invested capital (ROIC) through working capital management and an efficient investment program.

The Company is subject to maximum indebtedness levels according to the terms presented in Note 16.

Notes to Quarterly Information

Financial instrument by category

The table below shows the Company's financial instruments by category. Fair values of financial instruments shown do not vary significantly from the balances shown in the Company and Consolidated statements of financial position.

	Company					
	6/30/14			12/31/13		
Description	Fair value through profit or loss	Loans and receivables	Amortized cost	Fair value through profit or loss	Loans and receivables	Amortized cost
Cash and cash equivalents and Marketable securities	262,568	-	-	512,755	-	-
Judicial deposits	36,632	-	-	90,695	-	-
Trade accounts receivable		410,832	-	-	389,860	-
Derivatives	-	-	-	107	-	-
Assets	299,200	410,832	-	603,557	389,860	-
Trade accounts payable	-	-	55,691	-	-	45,804
Loans and financing	-	-	7,099	-	-	8,431
Debentures	-	-	1,121,881	-	-	1,356,726
Derivatives	336	-	-	-	-	-
Taxes in installments	-	-	10,279	-	-	10,538
Payables for acquisition of subsidiaries	-	-	32,553	-	-	36,750
Liabilities	336	-	1,227,503	-	-	1,458,249

	Consolidated					
	6/30/14			12/31/13		
Description	Fair value through profit or loss	Loans and receivables	Amortized cost	Fair value through profit or loss	Loans and receivables	Amortized cost
Cash and cash equivalents and Marketable securities	534,027	-	-	646,654	-	-
Judicial deposits	41,529	-	-	95,540	-	-
Trade accounts receivable		644,488	-	-	566,262	-
Derivatives	-	-	-	107	-	-
Assets	575,556	644,488	-	742,301	566,262	-
Trade accounts payable	-	-	81,180	-	-	65,479
Loans and financing	-	-	166,894	-	-	118,449
Debentures	-	-	1,121,881	-	-	1,356,726
Derivatives	336	-	-	-	-	-
Taxes in installments	-	-	24,462	-	-	29,185
Payables for acquisition of subsidiaries	-	-	44,675	-	-	48,359
Liabilities	336	-	1,439,092	1,233	-	1,618,198

Notes to Quarterly Information

Fair value hierarchy

The Company holds only financial instruments qualified at level 2, corresponding to marketable securities in the consolidated amounts of R$ 501,603 at June 30, 2014 (R$ 625,786 at December 31, 2013) and derivatives in the consolidated amounts of R$ 366 asset at June 30, 2014 (R$ 107 liability at December 31, 2013).

The different levels are defined as follows:

- Level 1 - Prices (not adjusted) quoted in active markets for identical assets and liabilities.
- Level 2 - Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices).
- Level 3 - Assumptions for the asset or liability that are not based on observable market data (unobservable inputs).

a) *Estimated fair values*

Estimated fair value for financial instruments was developed using a pricing model applied individually to each transaction, taking into account future payment flows based on contractual terms, discounted to present value at rates obtained through the market interest curve, based on information obtained from the BM&FBovespa and ANBIMA websites.

Therefore a security's fair value corresponds to its value at maturity (redemption value) brought to present value using a discount factor (related to the maturity date) obtained from the market interest curve in *Reais*.

b) *Derivatives*

The hedge instruments contracted by the Company are non-deliverable forwards and interest rate *swaps* with no leverage component, margin call clause, daily adjustment or periodic adjustments. The assumptions used for calculation of assets and liabilities are broken down in the table below:

Notes to Quarterly Information

At June 30, 2014, the Company held the following swap operations:

Financial instruments – Derivatives receivable (Consolidated)

					Fair value (Accounting)							
Company strategy	Index rate - Assets	Assets	Index rate - Liabilities	Liabilities	Fair value	Amounts	Gain (loss) in mark to market	Currency/ index	Maturity	Notional value	Market	Counter party
Derivatives for debts hedge not assigned at fair value												
Swap - Hedge exchange rate	Dollar	3,764	78.55% do CDI	(4,100)	(336)	(549)	213	Dollar	4/2010 to 3/2016*	1,719	OTC	HSBC
		3,764		(4,100)	(336)	(549)	213					
Classified in current assets					(310)							
Classified in noncurrent assets					(26)							

* Monthly maturity

The Company recognized gains and losses on its derivative instruments. However, since they are hedging derivatives, these gains and losses minimized the impact of exchange-rate and interest-rate variation incurred by the indebtedness that the derivatives were hedging. At June 30, 2014, derivative instruments had the following impacts on consolidated income:

			Income	
Derivatives	Risk	Account	6/30/14	6/30/13
HSBC (SWAP)	Exchange variation -Interest - fair value adjustment	Financial income/ (financial expenses)	(457)	(519)
			(457)	(519)

Sensitivity analysis of derivatives

The Company carried out the sensitivity analysis for the main risks to which its financial instruments (including derivatives) are exposed, which basically refer to risks related to exchange and interest rate variations, as follows:

Exchange-rate variation

Fair value was calculated in accordance with projections made on the date of these quarterly information for future quotations of the US dollar obtained from BM&FBovespa. In the case of the scenarios, as determined by the abovementioned instruction, the stress percentages defined therein were added.

Notes to Quarterly Information

Assuming the notional exposure of indexed to variable interest rates above are maintained, the effects of dollar depreciation on the Company's consolidated quarterly information, by type of financial instrument, for the two different scenarios, would be as follows:

Contracts	Risk	Exposure	Fair value at 6/30/2014	Depreciation 25%	Depreciation 50%
SWAP Contract – HSBC Long position – Exchange variation	Dollar drop - US$	1,719	3,765	(941)	(1,882)
		1,719	3,765	(941)	(1,882)

Interest-rate variation

Market value was calculated in accordance with the projections on the date of these quarterly information for future quotations for each maturity date of principal and interest obtained on the BM&FBovespa. In the case of the scenarios, as determined by the abovementioned instruction, the stress percentages defined therein were added.

Assuming the exposure of financial instruments indexed to variable interest rates at June 30, 2014 is maintained, the effects of a higher interbank (CDI) on the Company's consolidated quarterly information, by type of financial instrument, for two different scenarios, would be as follows:

Contracts	Risk	Exposure	Fair value at 6/30/2014	Increase 25%	Increase 50%
SWAP Contract- HSBC Short position – Interest	CDI Increase	1,719	(4,100)	11	21
		1,719	(4,100)	11	21

Sensitivity analysis of financial assets and liabilities

The principal risks concerning the Company's operations relate to interbank (CDI) rate variations for promissory notes, debentures and marketable securities linked to the dollar exchange rate variation for loans and financing and marketable securities.

CDI Investments are recorded at fair value, in accordance with quotations disclosed by the corresponding financial institutions and the others refer mostly to banking deposit certificates and repurchase agreements, therefore the amount recorded for these securities shows no difference in relation to fair value.

Based on expectations stated in the FOCUS/Bacen report 06/27/14, a projection for the next 12 months was obtained, with an average of 11.88% for CDI and R$ 2.46 for the exchange rate (R$/US$).

Notes to Quarterly Information

In order to verify the sensitivity of the index on marketable securities held by the Company at June 30, 2014, three different scenarios were defined, based on the projection and, from then on, the variations of 25% and 50% were calculated.

For each scenario gross financial expense / (income) was calculated, not including the impact of taxes and the flow of maturities of each contract scheduled for 2014.

Transaction	Balance at June 30, 2014	Risk	Scenario I (Probable)	Scenario II	Scenario III
Marketable securities	55,822	Dólar	(6,526)	13,956	27,911
Rate subject to variation			2.46	1.65	1.10
Marketable securities	409,397	CDI	48,636	36,477	24,318
Rate subject to variation			11.88%	8.91%	5.94%

In order to verify the sensitivity of our debts index at June 30, 2014, three different scenarios were defined based on the projection, from which variations of 25% and 50% were calculated.

Gross financial expense was calculated for each scenario, not taking into consideration the impact of taxes and the flow of maturities of each contract scheduled for 2014.

The reporting date used for financing was June 30, 2014, and the indices were projected for one year and their sensitivity determined for each scenario.

Transaction	Balance at June 30, 2014	Risk (a)	Scenario I (Probable)	Scenario II	Scenario III
Debentures	**1,127,774**	CDI	133,980	167,474	200,969
			11.88%	14.85%	17.82%
Working capital	**82,771**	CDI	9,833	12,291	14,750
			11.88%	14.85%	17.82%
Working capital	**66,838**	Dollar	7,814	16,710	33,419
			2.46	2.75	3.30

(a) Rate subject to variation

Notes to Quarterly Information

Fair value

	Company			
	6/30/14		12/31/13	
	Book value	**Fair value**	**Book value**	**Fair value**
Assets				
Marketable securities	**251,410**	**251,410**	497,929	497,929
Judicial deposits	**36,632**	**36,632**	90,695	90,695
Trade accounts receivable	**410,832**	**410,832**	389,860	389,860
Derivatives	**-**	**-**	107	107
Liabilities				
Trade accounts payable	**55,691**	**55,691**	45,804	45,804
Debentures	**1,121,881**	**1,125,125**	1,356,726	1,365,658
Derivatives	**336**	**336**	-	-
Loans and financing:				
Other bank loans	**7,099**	**7,099**	8,431	8,431

	Consolidated			
	6/30/14		12/31/13	
	Book value	**Fair value**	**Book value**	**Fair value**
Assets				
Marketable securities	**501,603**	**501,603**	625,786	625,786
Judicial deposits	**41,529**	**41,529**	95,540	95,540
Trade accounts receivable	**644,488**	**644,488**	566,262	566,262
Derivatives	**-**	**-**	107	107
Liabilities				
Trade accounts payable	**81,180**	**81,180**	65,479	65,479
Debentures	**1,121,881**	**1,125,125**	1,356,726	1,365,658
Derivatives	**336**	**336**	-	-
Loans and financing:				
Bank loan - Banco do Brasil	**82,771**	**82,817**	23,884	23,954
Bank loan – Credit Agricole	**66,840**	**66,840**	70,623	70,623
Other bank loans	**17,283**	**17,283**	23,942	23,942
	166,894	**166,940**	118,449	118,519

Notes to Quarterly Information

25. Related parties

In the periods ended June 30, 2014 and 2013, the Company entered into transactions with related parties within its normal operating context, as shown below:

a) Transactions related to services rendered between Company and related parties

	6/30/2014	12/31/2013
Current assets – Customers		
CientificaLab	67	63
CERPE	173	78
Previlab	83	59
	323	200
Current liabilities – Other accounts payable		
DASA RE (i)	194	73
Sérgio Franco (ii)	4,793	2,687
	4,987	2,760

Income for the period	6/30/2014	6/30/2013
Service revenue		
CientificaLab	312	1,4438
CERPE	536	338
Previlab	374	511
	1,222	2,287
Cost of services provided		
DASA RE (i)	448	629
Sérgio Franco (ii)	18,304	10,980
	18,752	11,609

(i) Amounts corresponding to property rent.
(ii) Amounts corresponding to clinical analysis services.

Transactions with related parties, as shown above, are carried out at cost and eliminated in the consolidated quarterly information.

Notes to Quarterly Information

b) Advances for future capital contribution (AFAC)

	6/30/14	12/31/13
CientificaLab Produtos Laboratoriais e Sistemas Ltda.	**28,000**	25,000

c) Management compensation

Total management compensation, including fixed compensation and bonuses, was R$1,332 in the first semester of 2014 (R$1,340 in the first semester of 2013), paid to the members of the Board of Directors (5 members in the first semester of 2014 and of 2013), and R$5,800 in the first semester of 2014 and R$4,246 in the first semester of 2013, paid to statutory officers (11 statutory officers in the first quarter of 2014 and 9 in the first semester of 2013).

Changes occurred in share-based compensations are disclosed in Note 20 (a). There are no additional benefits to Company management.

d) Assignment of credits

Subsidiary Pro Echo (assignor) and the Company (assignee) entered into a credit assignment agreement on February 3, 2014, whereby the assignor assigns credits owned thereby to the assignee, amounting to R$ 44,889, arising from intercompany loan agreements entered into with the following subsidiaries: (i) Laboratórios Médicos Dr.Sérgio Franco, amounting to R$ 36,803, (ii) Check-up UP, amounting to R$ 4,726, and (iii) CRMI, amounting to $ 3,360. In consideration of the assignment, the Company pays R$ 44,889 to subsidiary Pro Echo (assignor) at May 2, 2014

e) Transactions *between the Company and other related parties*

Transactions with related parties are conducted at average regular market values, deadlines and rates prevailing on the respective dates and may be continuous.

The related parties that are not included in the consolidated quarterly information are as follows:

Link Consultoria em Medicina Diagnóstica Ltda.: an entity held by Alcione Moya Aprilante, shareholder of Previlab Análises Clínicas Ltda., which is a Company controlled by the DASA. It provides advisory services regionally in the management of health companies, and has market know-how, relationship with physicians practicing in the region where Previlab operates, as well as recognition by potential health professionals and customers.

Medparts Participações e Negócios Ltda.: entity held by Doctor Luciano Flávio Freitas de Almeida, member of Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda. – CERPE, which renders services to the Company, providing advisory services on business management of medical companies, with market know-how, relationship with local physicians, and recognition of potential professionals and customers in healthcare field.

Notes to Quarterly Information

Amar Administradora de Bens Próprios Ltda.: a company owned by M.D. Alcione Moya Aprilante and his wife, Melania Angelieri Cunha Aprilante. M.D. Alcione is a member of Previlab (a Company's subsidiary), which is the lessor of properties owned by AMAR, which belonged to Melania Angelieri Cunha Aprilante.

César Antonio Biazio Sanches: shareholder of Análises Clínicas Ltda., owner of the property leased by Previlab, which is an entity controlled by the Company, located at Rua Alferes Franco, nº 408 - Limeira, SP.

A e C Consultores Ltda.: an entity held by Cezar Antonio Biázio Sanches, shareholder of Previlab Análises Clínicas Ltda., which is a Company controlled by DASA. It provides business advisory and support services in the Previlab business area, as well as advisory, coaching, training and assessment of Previlab's employees and service providers.

Pesmed – Pesquisas e Serviços Médicos Ltda.: a Company controlled by Mr. Emerson Leandro Gasparetto, our radiology and graphical methods officer (elected March 26, 2012) and his wife, also a medical professional, Dr. Taisa Pallu Davaus Gasparetto, for consulting services in the form of medical research and surveys for subsidiaries: CDPI – Clínica de Diagnósticos por Imagem Ltda, CRMI – Clínica de Ressonância e Multi Imagem Ltda. The amounts are calculated based on the number of reports actually prepared by Pesmed, with due regard for the amount corresponding to each type of report, as per the list prepared by Company, using the same system adopted for the other providers of services for the Company.

RMR Ressonância Magnética Ltda: a Company with shareholders jointly holding 33.24% of its capital who are the brothers of Mr. Romeu Cortês Domingues, chairman of the board of directors of the Company (elected April 26, 2011) , which provides medical services in the field of magnetic resonance imaging for these subsidiaries: CDPI – Clínica de Diagnósticos por Imagem Ltda; CRMI – Clínica de Ressonância e Multi Imagem Ltda; and Clínica de Ressonância e Multi-Imagem Caxias Ltda. Amounts are calculated based on revenue from magnetic resonance imaging services and numbers of exams produced by RMR, recognizing the corresponding charge for each type of report, as per the list prepared by the Company and using the same system adopted for the other providers of services for the Company.

Ultrascan Serviços de Imagem Ltda: Company owned by Eduardo Luiz Primo de Siqueira, who holds 7.5% of Clinica de Ressonância Multi-Imagem Petrópolis Ltda, which provides medical services in the imaging area for the controlled Company Clinica de Ressonância Multi-Imagem Petropolis Ltda. The amounts are calculated based on the imaging service revenue and the number of reports prepared by Ultrascan, subject to the amount corresponding to each report type, according to the subsidiary's table, and they should further comply with the same system adopted for the other service providers of subsidiary.

Notes to Quarterly Information

DMG Laboratório Médico Ltda: a franchise of the controlled Company Laboratórios Médicos Dr. Sérgio Franco Ltda., whose managing partner is Neusa de Godoy Bueno Joaquim, mother-in-law of the regional chief financial officer of the controlled Company Laboratórios Médicos Dr. Sérgio Franco Ltda., Carlos Fabio Ferreira Xavier. The franchise commission is calculated based on DMG's service revenue, subject to the same system adopted for the other franchisees.

Lâmina Laboratório de Patologia Prevenção de Câncer Ltda: an entity whose partner is Adilia Jane de Alcantara Segura, non-statutory medical officer of the Company, for clinical pathology services. The amounts are calculated based on the number of examinations effectively made by Lâmina, subject to the amount corresponding to each examination type, according to the Company table and pursuant to the same system adopted for the other services providers.

ECRD – Serviços Médicos de Radiologia Ltda: The Company's partner is Mr. Roberto Cortes Domingues, brother of Mr. Romeu Cortês Domingues, chairman of the Board of Directors (appointed on April 26, 2011), which provides medical services referring to MRI and radiology for subsidiaries CDPI – Clínica de Diagnósticos por Imagem Ltda., CRMI – Clínica de Ressonância e Multi Imagem Ltda. and Clínica de Ressonância e Multi-Imagem Caxias Ltda. and Clínica de Ressonância e Multi-Imagem Petropolis Ltda.

Amil Group (Amil International; Amico and Dix): Mr. Edson Godoy Bueno, together with Dulce Pugliese de Godoy Bueno, is the Company's controlling shareholder and also Chief Executive Officer of the Amil Group, to which the Company and its subsidiaries provide medical diagnosis services. The Company and its subsidiaries also engaged the Amil Group to provide employees' health plan management services.

Amil Impar / Amil Par: Mr. Edson Godoy Bueno and Dulce Pugliese de Godoy Bueno, controlling shareholders of the Company and also of Amil Impar and Amil Par, holding equity interest in hospitals in which the Company and its subsidiaries provide medical diagnosis services.

EGB 01 Empreendimentos e Participações Ltda.: Mr. Edson Godoy Bueno and Dulce Pugliese de Godoy Bueno, controlling shareholders of the Company and also of EGB, which has properties under lease with the Company and its subsidiaries.

Notes to Quarterly Information

The amount of such transactions with related parties is as follows:

		Assets/ (Liabilities) 6/30/2014			Assets/ (Liabilities) 12/31/2013		
		Services	Rents	Healthcare	Services	Rents	Healthcare
- Link Consult. em Medicina Diag. Ltda		(31)	-	-	(15)	-	-
- Medparts Particip. e Negócios Ltda.		-	-	-	-	-	-
- Amar Admin. de Bens Próprios Ltda.		-	(25)	-	-	-	-
- César Antonio Biazio Sanches		-	(6)		-	(6)	-
- A e C Consultores Ltda.		(33)	-	-	(5)	-	-
- Pesmed – Pesquisas e Serv. Médicos Ltda.		-	-	-	-	-	-
- RMR Ressonância Magnética Ltda.		-	-	-	-	-	-
- Ultrascan Serviços de imagem Ltda.		-	-	-	-	-	-
- DMG Laboratório Médico Ltda.		(86)	-	-	(18)	-	-
- Lâmina Lab.de Patologia Prev.de Câncer Ltda.		-	-	-	-	-	-
- ECRD – Serviços Médicos de Radiologia Ltda.		-	-	-	-	-	-
- Grupo AMIL (AMIL Internacional; Amico e Dix)	**(a)**	86,738	-	(1,403)	56,281	-	(27)
- AMIL Impar / AMIL Par	**(a)**	25,688	-	-	17,643	-	-
- EGB 01 Empreend. e Participações Ltda.				-	-	(184)	-

(a) the reported amount of asset balances for services rendered by the Company and its subsidiaries is net of provision for disallowance, as well as financial discounts granted.

	Income / (Expenses) 6/30/14			Income / (Expenses) 6/30/13		
	Services	Rents	Healthcare	Services	Rents	Healthcare
- Link Consult. em Medicina Diag. Ltda	(79)	-	-	(95)	-	-
- Medparts Particip. e Negócios Ltda.	(133)	-	-	(124)	-	-
- Amar Admin. de Bens Próprios Ltda.	-	(152)	-	-	(159)	-
- César Antonio Biazio Sanches	-	(55)	-	-	(41)	-
- A e C Consultores Ltda.	(208)	-	-	(197)	-	-
- Pesmed – Pesquisas e Serv. Médicos Ltda.	(142)	-	-	(201)	-	-
- RMR Ressonância Magnética Ltda.	(848)	-	-	(2,233)	-	-
- Ultrascan Serviços de imagem Ltda.	(95)	-	-	(75)	-	-
- DMG Laboratório Médico Ltda.	(547)	-	-	(472)	-	-
- Lâmina Lab.de Patologia Prev.de Câncer Ltda.	-	-	-	(113)	-	-
- ECRD – Serviços Médicos de Radiologia Ltda.	(900)	-	-	-	-	-
- Grupo AMIL (AMIL Internacional; Amico e Dix)	212,636	-	(16,278)	201,617	-	(8,179)
- AMIL Impar / AMIL Par	55,101	-	-	44,905	-	-
- EGB 01 Empreend. e Participações Ltda.	-	(2,888)	-	-	(2,556)	-

Notes to Quarterly Information

26. Financial and operating lease

Local currency leases

The Company leases goods recorded in property and equipment, subject to agreements as follows: with no renewal option, and contingent payment, with no covenants referring to dividends and interest on equity or additional debt. These contracts total an amount payable of R$ 7,341 until 2015 for the consolidated, given that the sum of R$ 6,032 of this amount is recorded in current liabilities and R$ 1,309 in noncurrent liabilities.

The average term of the contracts is 36 months and these are remunerated at interest rate varying from CDI + 1.53% p.a. to CDI + 2.00% p.a.

Future minimum payments under loans and financing (see Note 15) are segregated as follows:

	6/30/14					
	Company			Consolidated		
	Present value of minimum Lease Payments	Interest	Future minimum payments	Future minimum payments Future	Interest	Future minimum payments
Up to one year	-	-	-	6,032	129	6,161
One to five years	-	-	-	1,309	28	1,337
	-	**-**	**-**	**7,341**	**157**	**7,498**

	12/31/13					
	Company			Consolidated		
	Present value of minimum lease payments	Interest	Future minimum payments	Future minimum payments Future	Interest	Future minimum payments
Up to one year	2	-	2	8,028	171	8,199
One to five years	-	-	-	3,073	65	3,138
	2	-	2	11,101	236	11,337

Domestic finance lease agreements are included in property and equipment under devices and equipment, amounting to R$ 14,303 (R$ 15,236 at December 31, 2013) in Consolidated.

Notes to Quarterly Information

Foreign currency financial leases

The Company leases equipment used to provide services, according to lease agreements with purchase option, with no renewal option, and contingent payment, with no covenants referring to dividends and interest on equity or additional debt. The payment term is 84 months. For the first installment of a shortage of 6 months for the settlement was established, and the remaining payments on a quarterly and semiannually. The quarterly and semi-annual installments in U.S. dollars are translated into reais at the market exchange rate effective on the payment date, plus interest from 7.20% per annum to 8.35% per annum, the balance payable totaling R$4,591 by 2016, R$4,277 thereof being recorded under current liabilities and R$314 under noncurrent liabilities.

Future minimum payments are segregated as follows:

	6/30/14					
	Company			Consolidated		
	Present value of minimum lease payments	Interest	Future minimum payments	Present value of minimum lease payments	Interest	Minimum Future payments
Up to one year	3,363	182	3,545	4,277	231	4,508
One to five years	314	17	331	314	17	331
	3,677	**199**	**3,876**	**4,591**	**248**	**4,839**

	12/31/13					
	Company			Consolidated		
	Present value of minimum Lease payments	Interest	Future minimum payments	Present value of minimum lease payments	Interest	Minimum future payments
Up to one year	6,626	403	7,029	7,893	480	8,373
One to five years	1,803	109	1,912	2,140	130	2,270
	8,429	**512**	**8,941**	**10,033**	**610**	**10,643**

The international finance lease agreements are included in property and equipment as machinery and equipment, totaling R$7,198 (R$8,002 at December 31, 2013) - Company and R$7,761 (R$8,687 at December 31, 2013) - consolidated.

Notes to Quarterly Information

Operating lease

Future minimum property rent payable on operating leases not subject to cancellation in consolidated are the following:

	6/30/14			12/31/13		
	Fixed-income agreements	Variable income agreements	Total	Fixed-income agreements	Variable income agreements	Total
Within one year	125,207	3,718	128,925	100,046	4,123	104,169
More than one year, but less than five years	224,369	6,663	231,032	177,826	7,329	185,155
More than five years	131,364	464	131,828	98,812	270	99,082
	480,940	10,845	491,785	376,684	11,722	388,406

27. Net revenue

Reconciliation between gross revenues for tax purposes and net revenues and discounts stated in the income statements is as follows:

	Company		Consolidated	
	6/30/14	6/30/13	6/30/14	6/30/13
Gross revenue	1,054,912	959,091	1,476,878	1,338,952
Deductions:				
Taxes	(61,593)	(55,117)	(85,287)	(75,921)
Provision for and losses due to disallowance and default	(28,485)	(30,335)	(37,325)	(45,906)
Discounts	(3,203)	(3,944)	(4,720)	(4,205)
	961,631	869,695	1,349,546	1,212,920

Notes to Quarterly Information

28. Financial income

	Company		Consolidated	
	6/30/2014	**12/31/2013**	**6/30/2014**	**12/31/2013**
Financial expenses				
Interest	**(72,423)**	(50,928)	**(75,481)**	(59,451)
Monetary and exchange variation losses	**(864)**	(4,118)	**(1,369)**	(8,148)
Discounts granted (a)	**(2,304)**	(31)	**(6,025)**	(36)
Other	**(5,242)**	(3,754)	**(9,434)**	(5,926)
	(80,833)	(58,831)	**(92,309)**	(73,561)
Financial income				
Interest	**27,532**	8,718	**36,415**	12,031
Monetary and exchange variation losses	**1,069**	4,250	**1,429**	5,223
Other	**427**	16,228	**1,411**	17,213
	29,028	29,196	**39,255**	34,467
	(51,805)	(29,635)	**(53,054)**	(39,094)

(a) Discounts granted to customers in the amount of R$ 2,276 - Company and R$ 5,980 - Consolidated, due to commercial business trading.

29. Subsequent events

Merger of subsidiaries on July 1, 2014.

The Special Shareholders' Meeting held on July 1, 2014 approved decisions as follows:

a) The Merger was approved by the Company pursuant to articles No. 224, 225 and 227 of Law No. 6404/76 and Articles No. 1116 to 1118 of Law No. 10406 of January 10, 2002, which establishes the terms and conditions of the merger;

b) Ratified under the terms of paragraph 1 of Article. 227 of Law No. 6404/76, the appointment and engagement of appraiser Apsis Consultoria e Avaliações Ltda, as a company specialized in valuation reports for merger purposes;

c) Valuation reports approved with no qualification, which calculated equity of each merged Company based on their carrying value and balance sheet as at December 31, 2013, respectively, (i) R$ 45,141, related to Clínica de Diagnóstico por Imagem Ltda. (CDPI); (ii) R$ 14,679, related to Clínica de Ressonância e Multi-Imagem Ltda. (CRMI); (iii) R$ 116,517, related Laboratórios Médicos Dr. Sergio Franco Ltda.; (iv) R$ 720, related to Imagem e Diagnósticos Ltda.; (v) R$ 5,767, related to Multiimagem PET Ltda.; (vi) R$ 1,939, related to Clínica de Ressonância e Multi-Imagem Caxias Ltda.;

Notes to Quarterly Information

d) Merger of the entities by the Company approved with no qualification, with the consequent extinction of the entities merged, under the terms provided for the Merger. The entities merged will be succeeded by the Company in all its rights and obligations, under the terms of article 227 of Law No. 6404/76 and article 1116 of the Brazilian Civil Code. Since the Company directly and indirectly holds total capital stock of the entities merged, (i) the Company will not increase capital nor issue new shares as a result of the merger, (ii) it is exempt from preparation of valuation report at market value as mentioned in Article 264 of Law No. 6404/76 as the Company had already been exempted from compliance with this requirement by the Securities and Exchange Commission (CVM), and (iii) there will be no right to withdraw due to the merger.

Acquisition of common shares issued by the Company approved by CADE on July 16, 2014

In a judgment session held on July 16, 2014, the Brazil's Administrative Council for Economic Defense (CADE) approved the acquisition by Cromossomo Participações II S/A of common shares issued by the Company, as a result of which Edson de Godoy Bueno and Dulce Pugliese de Godoy Bueno (shareholders owning, indirectly, all of the capital stock of Cromossomo), will control, directly and indirectly, more than 70% of the Company's capital stock, pursuant to Concentration Act No. 08700.002372/2014-07. Such approval by CADE was conditional upon compliance with an Agreement on Control of Concentrations (ACC).
The ACC obliges Cromossomo' shareholders to formally adhere to the obligations that had been provided for in the Performance Commitment Instrument the Company executed with CADE, in the official papers for Concentration Act nº 08012.010038/2010-4.

Board of Directors' Meeting held on July 24, 2014. Change of Board of Directors members and Statutory Audit Committee

Request of resignation presented to the Company on July 17, 2014 by Mauricio Bittencourt Almeida Magalhaes, from the position of member of the Board of Directors to which he was elected at the Annual Shareholders' Meeting held on April 22, 2013, to hold office until the meeting to consider the closing balance sheet for 2014.
Appointment of Marcelo Noll Barboza as a substitute for the position of Board of Directors member previously held by Maurício Bittencourt Almeida Magalhães, who shall serve until the date of the next Shareholders' Meeting.
The composition of the Company's Board of Directors continues to comply with the independence requirements provided for in such regulations, since the directors Oscar de Paula Bernardes Neto and Carlos Fernando Costa are considered independent directors under the definition of the Listing Regulations.
Request of resignation presented by Maurício Bittencourt Almeida Magalhães in the letter dated July 17, 2014, to the position of member of CAE to which he was elected at the Board of Director' Meeting held on April 22, 2013, and elected Marcelo Noll Barboza to substitute him, as a member with no specific denomination, for the term of office up to April 21, 2023 – together with other CAE members.

Notes to Quarterly Information

Board of Directors' Meeting held on July 24, 2014. Change of Board of Directors members and Statutory Audit Committee

On July 24, 2014, the Board of Directors accepted Marcelo Rucker's request of resignation from the position of People Director, which will be extinguished.
There was election, under a unified term of office jointly with the other members of the Board of Directors until the Annual Shareholders' Meeting approving the accounts for fiscal year ending December 31, 2015, of Adriano Brito da Costa Lima to the position of Vice Chairman of Human Resources with the same powers previously assigned to the People Director, and Lilian Cristina Pacheco Lira to the position of Director of Risk Management, Compliance and Internal Control, to be held jointly with the position of Legal Director.

* * * *

Dickson Esteves Tangerino **CEO**	**Márcio Ramos Fernandes** **Financial Director and Vice-President**
Carlos Elder Maciel de Aquino **Chief Accounting Officer and Infrastructure**	**Paulo Bokel Catta-Preta** **Investor Relations Director and CFO**

Daniel Vendramini da Silva
TC-CRC 1SP125812/O-1

Other Information Considered Relevant by the Company

Shareholding structure

Controlling shareholders, managing officers and outstanding shares

	Position at June 30, 2014			
Shareholders	**Common shares (unit)**	**%**	**Total shares (unit)**	**%**
Controllers	224,308,396	71.94%	224,308,396	71.94%
Board of directors	7,449,953	2.39%	7,449,953	2.39%
Staff of officers	111,728	0.04%	111,728	0.04%
Statutory Audit Committee	1	0.00%	1	0.00%
Treasury stock	1,052,459	0.34%	1, 052,459	0.34%
Outstanding shares	78,880,478	25.30%	78, 880,478	25.30%
Total of shares	**311,803,015**	**100.00%**	**311,803,015**	**100.00%**

	Position at June 30, 2013			
Shareholders	**Common shares (unit)**	**%**	**Total shares (unit)**	**%**
Board of directors	7,470,953	2.40%	7,470,953	2.40%
Staff of officers	69,866	0.02%	69,866	0.02%
Statutory Audit Committee	1	0.00%	1	0.00%
Treasury stock	1,159,035	0.37%	1,159,035	0.37%
Outstanding shares	303,103,160	97.21%	303,103,160	97.21%
Total of shares	**311,803,015**	**100.00%**	**311,803,015**	**100.00%**

At June 30, 2014 and 2013, the Company did not have a Supervisory Board.

Arbitration clause

The Company is bound to arbitration by the Market Arbitration Chamber, pursuant to the arbitration clause provided for in its articles of incorporation.

Independent auditor's review report on quarterly financial information

A free translation from Portuguese into English of Independent Auditor's Review Report on individual quarterly financial information prepared in accordance with Accounting Pronouncement CPC 21 (R1) - Interim Financial Reporting and consolidated interim quarterly financial information prepared in accordance with CPC 21 (R1) and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB)

INDEPENDENT AUDITOR'S REVIEW REPORT ON QUARTERLY FINANCIAL INFORMATION

The Shareholders, Board of Directors and Officers
Diagnósticos da América S.A.
São Paulo – SP

Introduction

We have reviewed the accompanying individual and consolidated interim financial information of Diagnósticos da America S.A. and subsidiaries (the "Company"), contained in the Quarterly Information Form (ITR) for the quarter ended June 30, 2014, which comprises the balance sheet as at June 30, 2014 and the related statements of income, and statements of comprehensive income for the three and six-month periods then ended, and the statements of changes in equity and statements of cash flow for the six-month period then ended, including accompanying notes.

Management is responsible for the preparation of the individual interim financial information in accordance with Accounting Pronouncement CPC 21 (R1) - Interim Financial Reporting, and consolidated interim financial information in accordance with CPC 21 (R1) and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the fair presentation of this information in conformity with the standards issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Financial Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Review Engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independent auditor's review report on quarterly financial information

Conclusion on the individual interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the individual interim financial information included in the quarterly financial information referred to above is not prepared, in all material respects, in accordance with CPC 21 (R1) applicable to the preparation of Quarterly Information (ITR), and presented consistently with the standards issued by the Brazilian Securities and Exchange Commission (CVM).

Conclusion on the consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the consolidated interim financial information included in the quarterly financial information referred to above is not prepared, in all material respects, in accordance with CPC 21 (R1) and IAS 34 applicable to the preparation of Quarterly Information (ITR), and presented consistently with the standards issued by the Brazilian Securities and Exchange Commission (CVM).

Other matters

Statements of value added

We also reviewed the individual and consolidated statements of value added (SVA), for the six-month period ended June 30, 2014, prepared under the responsibility of Company management, whose presentation in the interim financial information is required by the standards issued by the Brazilian Securities and Exchange Commission (CVM), applicable to preparation of Quarterly Information (ITR) and considered supplementary information under IFRS, which do not require SVA presentation. These statements were submitted to the same review procedures previously described and, based on our review, nothing has come to our attention that would make us believe that they were not prepared, in all material respects, consistent with the overall individual and consolidated interim financial information.

São Paulo, August 11, 2014.

ERNST & YOUNG
Auditores Independentes S.S.
CRC-2SP015199/O-6

Antonio Carlos Fioravante
Accountant CRC-1SP184973/O-0

Rita de C. S. de Freitas
Accountant CRC-1SP214160/O-5

Opinions and Statements/Statement of Officers on the Quarterly Information

Observing the provision of article 25 of Ruling No. 480/09 of December 7, 2009, the Board represents that it has reviewed, discussed and agreed with the Quarterly information (Company and Consolidated) for period ended June 30, 2014.

Barueri, August 11, 2014.

CEO - Dickson Esteves Tangerino

Financial Director and Vice-President – Márcio Ramos Fernandes

Investor Relations Officer and Financial and CFO - Paulo Bokel Catta-Preta

Chief Accounting Officer and Infrastructure - Carlos Elder Maciel de Aquino

Opinions and Declarations/Statement of Officers on the Independent Auditors Report

In compliance with the provisions of article 25, Instruction # 480/09, of December 7, 2009, the Staff of Officers represents that it has reviewed, discussed and agreed with the opinion expressed in the Independent Auditors' Review Report, dated August 11, 2014, related to the quarterly information (Company and Consolidated) for the period ended on June 30, 2014.

Barueri, August 11, 2014.

CEO - Dickson Esteves Tangerino

Financial Director and Vice-President – Márcio Ramos Fernandes

Investor Relations Officer and Financial and CFO - Paulo Bokel Catta-Preta

Chief Accounting Officer and Infrastructure - Carlos Elder Maciel de Aquino